

ORIGINAL
JFUS Rec'd PCT/PTO 29 NOV 2001

FORM PTO-1300 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER Le A 33 535	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/980242	
INTERNATIONAL APPLICATION NO. PCT/EP00/04431		INTERNATIONAL FILING DATE 16 May 2000 (16.05.00)		PRIORITY DATE CLAIMED 29 May 1999 (29.05.99)	
TITLE OF INVENTION SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THEIR USE AS ADENOSINE UPTAKE INHIBITORS					
APPLICANT(S) FOR DO/EO/US BISCHOFF, et al.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input checked="" type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: 1) Certificate of Mailing under 37 C.F.R. 1.10; 2) Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b); 3) Information Disclosure Citation (Modified Form PTO-1449) and references cited therein 4) Return Receipt Postcard.</p>					
Date of Deposit: NOV 29 2001					
Express Mail Label No.: ET677597759US					

FORM PTO-1390 (REV. 11-2000) page 2 of 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bischoff, et al.

Group Art Unit:

Serial No: National Stage Filing of PCT /EP00/04431 Examiner:

Filed: herewith

For: Substituted Phenylcyclohexane Carboxylic Acid Amides and Their Use as Adenosine

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

This preliminary amendment is submitted in the above-identified national stage application of PCT/EP00/04431 filed on even date herewith.

Please amend the above-identified application as follows:


In the claims:

Please cancel claims 7 and 17-20.

Please add new claims 21-62 as shown below.

Please amend claim 1-6, 8-13, and 16 as follows:

1. (Amended) Compounds of the general formula (I)



in which

A, D, E and G are identical or different and represent CH groups or nitrogen atoms,

L^1 and L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy and (C₁-C₆)-alkoxycarbonyl,

R^1 represents the CH₂-OH group, or
represents a radical of the formula CO-NR⁴R⁵,

in which

R⁴ and R⁵ are identical or different and each represents hydrogen or
(C₁-C₆)-alkyl,

R^2 represents (C₃-C₈)-cycloalkyl,
represents (C₁-C₈)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR⁶,
represents a 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or
represents a 4- to 8-membered saturated heterocycle which contains a radical of the formula NR⁷ and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C₃-C₈)-cycloalkyl, (C₁-C₈)-alkyl which is optionally interrupted by an oxygen or sulphur atom, the 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a

further oxygen or sulphur atom and optionally (C₁-C₈)-alkyl which is interrupted by a radical of the formula NR⁶ and optionally the 4- to 8-membered saturated heterocycle which contains a radical NR⁷ and optionally additionally one nitrogen, oxygen or sulfur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula -NR⁸R⁹

in which

R⁶ and R⁷ are identical or different and each represents hydrogen, (C₁-C₆)-alkyl, hydroxy-(C₁-C₆)-alkyl or (C₃-C₇)-cycloalkyl,

R⁸ and R⁹ are identical or different and each represents hydrogen, (C₁-C₆)-alkyl, or (C₃-C₇)-cycloalkyl,

or

R⁸ and R⁹ together with the nitrogen atom form a 4- to 8-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR¹⁰,

in which

R¹⁰ represents hydrogen, (C₁-C₆)-alkyl or (C₃-C₇)-cyloalkyl,

and

R³ represents a phenyl, naphthyl, pyrimidinyl, pyridyl, furyl or thienyl ring, where the rings are optionally mono- or polysubstituted by radicals selected from the group

consisting of halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy and (C₁-C₆)-alkoxycarboxyl,

and their enantiomers and diastereomers and their respective salts, hydrates and prodrugs.

2. (Amended) Compounds according to Claim 1

where

A, D, E and G each represents the CH group,

or one of the radicals A, D, E and G represents a nitrogen atom and the others each represent the CH group,

L₁ and L₂ are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, fluorine, chlorine, cyano, trifluoromethyl and trifluoromethoxy,

R¹ represents the -CH₂-OH group, or
represents a radical of the formula -CO-NR⁴R⁵,

in which

R⁴ and R⁵ are identical or different and each represents hydrogen or
(C₁-C₃)-alkyl,

R² represents (C₃-C₇)-cycloalkyl,

represents (C₁-C₆)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR⁶,

represents a 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or

represents a 5- to 7-membered saturated heterocycle which contains a radical of the formula NR⁷ and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C₃-C₇)-cycloalkyl, (C₁-C₆)-alkyl which is optionally interrupted by an oxygen or sulphur atom, the 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C₁-C₆)-alkyl which is interrupted by a radical NR⁶ and optionally the 5- to 7-membered saturated heterocycle which contains a radical of the formula NR⁷ and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by one hydroxyl group and/or by a radical of the formula -NR⁸R⁹,

in which

R⁶ and R⁷ are identical or different and each represents hydrogen, (C₁-C₄)-alkyl, hydroxy-(C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

R⁸ and R⁹ are identical or different and each represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10} ,

in which

R^{10} represents hydrogen, (C_1-C_4) -alkyl or (C_3-C_6) -cycloalkyl,

and

R^3 represents a phenyl, pyridyl or thienyl ring which is optionally mono or polysubstituted by radicals selected from the group consisting of fluorine, chlorine, cyano, trifluoromethyl and trifluoromethoxy,

and their enantiomers and diastereomers and their respective salts, hydrates and prodrugs.

3. (Amended) Compounds according to Claim 1 or 2

where

A, D and E each represent the CH group,

G represents a nitrogen atom or represents the CH group,

L^1 and L^2 each represent hydrogen,

R^1 represents a radical of the formula $-CO-NR^4R^5$,

in which

R^4 and R^5 each represent hydrogen,

R^2 represents (C₁-C₄)-alkyl which is optionally interrupted by an oxygen atom, or represents a 4- R^7 -piperazin-1-yl radical,

where (C₁-C₄)-alkyl, which is optionally interrupted by an oxygen atom, is substituted by a hydroxyl group or by a radical of the formula $-NR^8R^9$,

in which

R^7 represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a morpholine radical,

and

R^3 represents a phenyl or pyridyl radical which may optionally be mono- or polysubstituted by fluorine,

and their enantiomers and diastereomers and their respective salts, hydrates and prodrugs.

4. (Amended) Compounds according to Claim 1


where

the radical R^1 represents a radical of the formula $CO-NR^4R^5$ where R^4 and R^5 are hydrogen.

and


the other radicals are as defined in Claim 1.

5. (Amended) Compounds according to Claim 1, characterized by the following stereochemistry according to formula (Ia):



where the substituents R^1 , R^2 , R^3 , L^1 and L^2 and the radicals A, D, E and G are each as defined in Claim 1.

6. (Amended) Compounds according to Claim, having structural formula Ib and characterized by the following stereochemistry according to formula (Ib)



in which

R¹ represents a group -C(O)-NH₂,

R² represents (C₁-C₄)-alkyl which is substituted at the terminal C atom by a hydroxyl group,

R³ represents a phenyl ring which is optionally substituted in the para position by fluorine,


or

represents a pyridyl radical,

and their diastereomers and their respective salts, hydrates and prodrugs.


7. (Canceled) Compounds of the general formula (I) of the following structures:

(S)-N- {[(1R,2R)-2- {4- {[2-(3-hydroxypropyl)-1H-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:




and their salts, hydrates and, if appropriate, their prodrugs.

(S)-N-{{[(1R,2R)-2-{4-{{[2-(2-hydroxymethyl)-1H-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:




(S)-N-{{[(1R,2R)-2-{4-{{[2-(2-hydroxyethyl)-1H-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl]carbonyl}-phenylglycinamide:


(S)-N-{{[(1R,2R)-2-{4-{{[2-(3-hydroxypropyl)-1H-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl]carbonyl}-(3-pyridyl)glycinamide:



(S)-N-{{(1*R*,2*R*)-{4-{2-[2-morpholin-4-yl-methyl]-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl]carbonyl}-phenylglycinamide:




(S)-N-{{[(1*R*,2*R*)-2-{4-{[2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl]methyl}-phenyl]-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)] glycinamide:



8. (Amended) Process for preparing compounds of the general formula (I) according to Claim 1, characterized in that

(A) compounds of the general formula (II)




L^2 is as defined above in claim 1,

T represents (C₁-C₄)-alkyl,

and

V represents a suitable leaving group,

are initially converted by reaction with compounds of the general formula (III)




in which

A, D, E, G, and L¹ are each as defined above in claim 1

and

R¹¹ has the meaning of R² given above in claim 1, where amino and hydroxyl functions are optionally blocked by suitable amino- or hydroxyl- protective groups,


in inert solvents, depending on the definition of R^{II} optionally in the presence of a base, into the compounds of the general formula (IV)



in which

R^{11} , A, D, E, G, L^1 , L^2 and T are each as defined above in claim 1,

which are converted in a subsequent step using acids or bases into the corresponding carboxylic acids of the general formula (V)




in which

R^{11} , A, D, E, G, L^1 , L^2 are each as defined above in claim 1,

which are, if appropriate, activated, by conversion into a corresponding carboxylic acid derivative,

and which are subsequently reacted with compounds of the general formula (VI) or salts thereof



in which

R^1 and R^3 are each as defined above in claim 1


in inert solvents,

and, if R^{11} carries one of the abovementioned protective groups, this is optionally removed by customary methods either in the hydrolysis to the acids (IV) \rightarrow (V) or after the reaction with the compounds of the general formula (VI),

or

(B) if R^2 represents a saturated heterocycle which is attached directly to the imidazole ring via a nitrogen atom,

the above mentioned compounds of the general formula (II) are initially converted with compounds of the general formula (IIIa)




in which

A, D, E, G and L^1 are each as defined above in claim 1

and

Y represents halogen or mesylate,

in inert solvents into the corresponding compounds of the formula (VII)



in which

Y, A, D, E, G, L¹, L² and T are each as defined above in claim 1,


which are reacted in a subsequent step with compounds of the general formula
(VIII)



in which

R¹² and R¹³ together with the nitrogen atom form a heterocycle according to the
definition of R² given in claim 1


to give compounds of the general formula (IX)



in which

A, D, E, G, L¹, L², R¹², R¹³ and T are each as defined above in claim 1,

which are, in the subsequent steps, converted as described under (A) by hydrolysis into the corresponding carboxylic acids of the general formula (X)




in which

A, D, E, G, L¹, L², R¹² and R¹³ are each as defined above in claim 1

and these compounds are finally reacted with the compounds of the general formula (VI) according to known methods for preparing amides from carboxylic acids and amines and converted into the compounds of the general formula (I)

where the compounds of the general formula (I) obtained according to process variant (A) or (B) can, if appropriate, subsequently be converted into the corresponding salts.

9. (Amended) Compounds of the general formula (IV)




in which

A, D, E, G, L¹, L², R¹¹ and T are each as defined above in claim 1,

and their enantiomers and diastereomers and their respective salts.

10. (Amended) Compounds of the general formula (V)




in which

A, D, E, G, L¹, L² and R¹¹ are each as defined above in claim 1,

and their enantiomers and diastereomers and their respective salts.

11. (Amended) Compounds of the general formula (VII)




in which

A, D, E, G, L¹, L², Y and T are each as defined above in claim 1,

and their enantiomers and diastereomers and their respective salts.

12. (Amended) Compounds of the general formula (IX)




in which

A, D, E, G, L¹, L², R¹², R¹³ and T are each as defined above in claim 1,

and their enantiomers and diastereomers and their respective salts.

13. (Amended) Compounds of the general formula (X)



in which

A, D, E, G, L¹, L², R¹³, R¹² are each as defined above in claim 1.

and their enantiomers and diastereomers and their respective salts.

16. (Amended) A pharmaceutical composition comprising a compound of the general formula (I) according to Claim 1 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.

21. (New) Compounds according to Claim 2

where


the radical R^1 represents a radical of the formula $CO-NR^4R^5$ where R^4 and R^5 are hydrogen

and

the other radicals are as defined in Claim 2.


New claims 22-24 have been broken out of original improper multiple dependent claim 5.

22. (New) Compounds according to Claim 2, characterized by the following stereochemistry according to formula (Ia):




where the substituents R^1 , R^2 , R^3 , L^1 and L^2 and the radicals A, D, E and G are each as defined in Claim 2.

23. (New) Compounds according to Claim 3, characterized by the following stereochemistry according to formula (1a):




where the substituents R^1 , R^2 , R^3 , L^1 and L^2 and the radicals A, D, E and G are each as defined in Claim 3.

24. (New) Compounds according to Claim 4, characterized by the following stereochemistry according to formula (1a):



where the substituents R^1 , R^2 , R^3 , L^1 and L^2 and the radicals A, D, E and G are each as defined in Claim 4.

25. (New) Compounds according to Claim 2, having structural formula 1b and characterized by the following stereochemistry according to formula (1b)



in which

R¹ represents a group -C(O)-NH₂,

R² represents (C₁-C₄)-alkyl which is substituted at the terminal C atom by a hydroxyl group,


R³ represents a phenyl ring which is optionally substituted in the para position by fluorine,

or

represents a pyridyl radical,

and their diastereomers and their respective salts, hydrates and prodrugs.

26. (New) Compounds according to Claim 3, having structural formula 1b and characterized by the following stereochemistry according to formula (1b)



in which

R^1 represents a group $-C(O)-NH_2$,

R^2 represents (C_1-C_4) -alkyl which is substituted at the terminal C atom by a hydroxyl group,


R^3 represents a phenyl ring which is optionally substituted in the para position by fluorine,

or

represents a pyridyl radical,

and their diastereomers and their respective salts, hydrates and prodrugs.

27. (New) Compounds according to Claim 4, having structural formula Ib and characterized by the following stereochemistry according to formula (Ib)



in which

R^1 represents a group $-C(O)-NH_2$,


or

represents a pyridyl radical,


and their diastereomers and their respective salts, hydrates and prodrugs.

29. (New) Compounds of the general formula (I) of the following structures:


(S)-N-{{[(1*R*,2*R*)-2-{4-{{2-(hydroxymethyl)-1*H*-benzimidazol-1-yl}methyl}-phenyl}-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:




(S)-N-{{[(1*R*,2*R*)-2-{4-{{2-(2-hydroxyethyl)-1*H*-benzimidazol-1-yl}methyl}-phenyl}-cyclohex-1-yl]carbonyl}-phenylglycinamide:




(S)-N-{{[(1*R*,2*R*)-2-{4-{{2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl}methyl}-phenyl}-cyclohex-1-yl]carbonyl}-(3-pyridyl)glycinamide:



(S)-N-{{(1*R*,2*R*)-2-{4-[2-(morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide:



(S)-N-{{(1*R*,2*R*)-2-{4-[2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-(4-fluorophenyl)glycinamide:



and their salts, hydrates and, if appropriate, their prodrugs.

30. (New) The process of claim 8 wherein T represents methyl or tert-butyl.
31. (New) The process of claim 8 wherein V represents halogen, mesylate, or tosylate.
32. (New) The process of claim 31 wherein V represents bromine.
33. (New) The process of claim 8 wherein said carboxylic acid derivative of a compound of formula V is a carbonyl halide, carboxylic anhydride or carboxylic ester.
34. (New) The process of claim 8 wherein Y of formula IIIa is chlorine or bromine.
35. (New) The process of claim 8 wherein the steps of converting the compounds of general formula I into the corresponding salts, as provided in the final paragraph of claim 8, is carried out by reaction with an acid.
36. (New) A pharmaceutical composition comprising a compound of the general formula (I) according to Claim 2 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.

37. (New) A pharmaceutical composition comprising a compound of the general formula (I) according to Claim 3 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.
38. (New) A pharmaceutical composition comprising a compound of the general formula (I) according to Claim 4 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.
39. (New) A pharmaceutical composition comprising a compound of the general formula (I) according to Claim 5 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.
40. (New) A pharmaceutical composition comprising a compound of the general formula (I) according to Claim 6 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.
41. (New) A pharmaceutical composition comprising a compound of the general formula (I) according to Claim 7 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.
42. (New) A method of treatment or prophylaxis of a disorder in a mammal comprising administering an effective amount of a compound of claim 1.

43. (New) The method of claim 42 wherein said disorder is an ischaemic disorder of the cardiovascular system.
44. (New) The method of claim 42 wherein said mammal is human.
45. (New) A method of treatment or prophylaxis of a disorder in a mammal comprising administering an effective amount of a compound of claim 2.
46. (New) The method of claim 45 wherein said disorder is an ischaemic disorder of the cardiovascular system.
47. (New) The method of claim 45 wherein said mammal is human.
48. (New) A method of treatment or prophylaxis of a disorder in a mammal comprising administering an effective amount of a compound of claim 3.
49. (New) The method of claim 48 wherein said disorder is an ischaemic disorder of the cardiovascular system.
50. (New) The method of claim 48 wherein said mammal is human.

51. (New) A method of treatment or prophylaxis of a disorder in a mammal comprising administering an effective amount of a compound of claim 4.
52. (New) The method of claim 51 wherein said disorder is an ischaemic disorder of the cardiovascular system.
53. (New) The method of claim 51 wherein said mammal is human.
54. (New) A method of treatment or prophylaxis of a disorder in a mammal comprising administering an effective amount of a compound of claim 5.
55. (New) The method of claim 54 wherein said disorder is an ischaemic disorder of the cardiovascular system.
56. (New) The method of claim 54 wherein said mammal is human.
57. (New) A method of treatment or prophylaxis of a disorder in a mammal comprising administering an effective amount of a compound of claim 6.
58. (New) The method of claim 57 wherein said disorder is an ischaemic disorder of the cardiovascular system.

59. (New) The method of claim 57 wherein said mammal is human.
60. (New) A method of treatment or prophylaxis of a disorder in a mammal comprising administering an effective amount of a compound of claim 29.
61. (New) The method of claim 60 wherein said disorder is an ischaemic disorder of the cardiovascular system.
62. (New) The method of claim 60 wherein said mammal is human.

Remarks / Explanations

As a result of this preliminary amendment, claims 1-6, 8-16, and 21-62 are pending in the application. Claims 7 and 17-20 have been canceled.

New claim 21 has been broken out of original improper multiple dependent claim 4. New claims 22-24 have been broken out of original improper multiple dependent claim 5. New claims 25-28 have been broken out of original improper multiple dependent claim 6. New claim 29 replaces original claim 7 and reflects the original PCT claim. New claims 30-35 claim material deleted from process claim 8. New claims 36-41 are broken out of original claim 16, drawn to medicaments including the compounds of claims 1-7. New claims 42-62 replace original "use" claims 19 and 20.

No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **“Version with markings to show changes made.”**


In view of the above amendments and explanations, this application is deemed to be in condition for allowance, and allowance is accordingly requested.

Respectfully submitted,

Reg. No. 31018

Phone: (203) 812-2712

Date: 11/28/01



William F. Gray


Bayer Corporation

400 Morgan Lane

West Haven, CT 06516-4175

Version with markings to show changes made:

1. (Amended) Compounds of the general formula (I)



in which

A, D, E and G are identical or different and represent CH groups or nitrogen atoms,

L¹ and L² are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy [or] and (C₁-C₆)-alkoxycarbonyl,

R¹ represents the CH₂-OH group, or
represents a radical of the formula CO-NR⁴R⁵,

in which

R⁴ and R⁵ are identical or different and each represents hydrogen or
(C₁-C₆)-alkyl,

R² represents (C₃-C₈)-cycloalkyl,
represents (C₁-C₈)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR⁶,

represents a 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or

represents a 4- to 8-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,

where $(\text{C}_3\text{-C}_8)$ -cycloalkyl, $(\text{C}_1\text{-C}_8)$ -alkyl which is optionally interrupted by an oxygen or sulphur atom, the 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom and optionally $(\text{C}_1\text{-C}_8)$ -alkyl which is interrupted by a radical of the formula NR^6 and optionally the 4- to 8-membered saturated heterocycle which contains a radical NR^7 and optionally additionally one nitrogen, oxygen or sulfur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula $-\text{NR}^8\text{R}^9$

in which

R^6 and R^7 are identical or different and each represents hydrogen, $(\text{C}_1\text{-C}_6)$ -alkyl, hydroxy- $(\text{C}_1\text{-C}_6)$ -alkyl or $(\text{C}_3\text{-C}_7)$ -cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, $(\text{C}_1\text{-C}_6)$ -alkyl, or $(\text{C}_3\text{-C}_7)$ -cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 4- to 8-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10} ,

in which

R^{10} represents hydrogen, (C_1-C_6) -alkyl or (C_3-C_7) -cyloalkyl,

and

R^3 represents a phenyl, naphthyl, pyrimidinyl, pyridyl, furyl or thienyl ring, where the rings are optionally mono- or polysubstituted by radicals selected from the group consisting of halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C_1-C_6) -alkyl, (C_1-C_6) -alkoxy and (C_1-C_6) -alkoxycarboxyl,

and their enantiomers and diastereomers and their respective salts, hydrates and[, if appropriate, their] prodrugs.

2. (Amended) Compounds according to Claim 1

where

A, D, E and G each represents the CH group,

or one of the radicals A, D, E and G represents a nitrogen atom and the others each represent the CH group,

L_1 and L_2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, fluorine, chlorine, cyano, trifluoromethyl and trifluoromethoxy,

R¹ represents the -CH₂-OH group, or
represents a radical of the formula -CO-NR⁴R⁵,

in which

R⁴ and R⁵ are identical or different and each represents hydrogen or
(C₁-C₃)-alkyl,

R² represents (C₃-C₇)-cycloalkyl,
represents (C₁-C₆)-alkyl which is optionally interrupted by an oxygen or sulphur
atom or by a radical NR⁶,
represents a 5- to 7-membered saturated heterocycle which is attached to the
imidazole ring via a nitrogen atom and which optionally contains a further
oxygen or sulphur atom, or
represents a 5- to 7-membered saturated heterocycle which contains a radical of
the formula NR⁷ and optionally additionally one nitrogen, oxygen or
sulphur atom,

where (C₃-C₇)-cycloalkyl, (C₁-C₆)-alkyl which is optionally interrupted by an
oxygen or sulphur atom, the 5- to 7-membered saturated heterocycle which is
attached to the imidazole ring via a nitrogen atom and which optionally contains
one further oxygen or sulphur atom and optionally (C₁-C₆)-alkyl which is
interrupted by a radical NR⁶ and optionally the 5- to 7-membered saturated
heterocycle which contains a radical of the formula NR⁷ and optionally
additionally one nitrogen, oxygen or sulphur atom are substituted by one hydroxyl
group and/or by a radical of the formula -NR⁸R⁹,

in which

R^6 and R^7 are identical or different and each represents hydrogen, (C₁-C₄)-alkyl, hydroxy-(C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

R^8 and R^9 are identical or different and each represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

or

R^8 and R^9 together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR^{10} ,

in which

R^{10} represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl, [.]

and

R^3 represents a phenyl, pyridyl or thienyl ring which is optionally mono or polysubstituted by radicals selected from the group consisting of fluorine, chlorine, cyano, trifluoromethyl and trifluoromethoxy,

and their enantiomers and diastereomers and their respective salts, hydrates and[, if appropriate, their] prodrugs.

3. (Amended) Compounds according to Claim 1 or 2

where

A, D and E each represent the CH group,

G represents a nitrogen atom or represents the CH group,

L¹ and L² each represent hydrogen,

R¹ represents a radical of the formula -CO-NR⁴R⁵,

in which

R⁴ and R⁵ each represent hydrogen,

R² represents (C₁-C₄)-alkyl which is optionally interrupted by an oxygen atom, or represents a 4-R⁷-piperazin-1-yl radical,

where (C₁-C₄)-alkyl, which is optionally interrupted by an oxygen atom, is substituted by a hydroxyl group or by a radical of the formula -NR⁸R⁹,

in which

R⁷ represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

R⁸ and R⁹ are identical or different and each represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

or

R⁸ and R⁹ together with the nitrogen atom form a morpholine radical,

and

R^3 represents a phenyl or pyridyl radical which may optionally be mono- or polysubstituted by fluorine,

and their enantiomers and diastereomers and their respective salts, hydrates and[, if appropriate, their] prodrugs.

4. (Amended) Compounds according to [any of] Claim[s] 1[to 3]


where

the radical R^1 represents a radical of the formula $CO-NR^4R^5$ where R^4 and R^5 are [as defined above] hydrogen.

and


the other radicals are as defined in Claim[s] 1 [to 3].

5. (Amended) Compounds according to [any of] Claim[s] 1 [to 4], characterized by the following stereochemistry according to formula (Ia):



where the substituents R^1 , R^2 , R^3 , L^1 and L^2 and the radicals A, D, E and G are each as defined in Claim[s] 1 [to 4].

6. (Amended) Compounds according to [any of] Claim[s] [1 to 5], having structural formula Ib and characterized by the following stereochemistry according to formula (Ib)



in which

R^1 represents a group $-C(O)-NH_2$,

R^2 represents (C_1-C_4) -alkyl which is substituted at the terminal C atom by a hydroxyl group,

R^3 represents a phenyl ring which is optionally substituted in the para position by fluorine,


or

represents a pyridyl radical,

and their diastereomers and their respective salts, hydrates and[, if appropriate, their] prodrugs.


7. (Canceled) Compounds of the general formula (I) of the following structures:

(S)-N-{[(1*R*,2*R*)-2-{4-[[2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:




and their salts, hydrates and, if appropriate, their prodrugs.

(S)-N-{[(1*R*,2*R*)-2-{4-[[2-hydroxymethyl)-1*H*-benzimidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:




(S)-N-{[(1*R*,2*R*)-2-{4-[[2-(2-hydroxyethyl)-1*H*-benzimidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl]carbonyl}-phenylglycinamide:


(S)-N-{{[(1*R*,2*R*)-2-{4-[[2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl]carbonyl}-(3-pyridyl)glycinamide:



(S)-N-{{[(1*R*,2*R*)-2-{4-[2-(2-morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl]carbonyl}-phenylglycinamide:




(S)-N-{{[(1*R*,2*R*)-2-{4-[[2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl]carbonyl}-(4-fluorophenyl) glycinamide:



8. (Amended) Process for preparing compounds of the general formula (I) according to Claim[s] 1 [to 7], characterized in that

[[A]] (A) compounds of the general formula (II)



in which


L^2 is as defined above in claim 1,

T represents (C₁-C₄)-alkyl, [preferably methyl or tert-butyl,]

and

V represents a suitable leaving group, [such as, for example, halogen, mesylate or tosylate, preferably bromine,]

are initially converted by reaction with compounds of the general formula (III)




in which

A, D, E, G, and L^1 are each as defined above in claim 1

and

R¹¹ has the meaning of R² given above in claim 1, where amino and hydroxyl functions are optionally blocked by suitable amino- or hydroxyl- protective groups,


in inert solvents, depending on the definition of R¹¹ optionally in the presence of a base, into the compounds of the general formula (IV)



in which

R¹¹, A, D, E, G, L¹, L² and T are each as defined above in claim 1,

which are converted in a subsequent step using acids or bases into the corresponding carboxylic acids of the general formula (V)




in which

R¹¹, A, D, E, G, L¹, L² are each as defined above in claim 1,

which are, if appropriate, activated, [in particular] by conversion into a corresponding carboxylic acid derivative, [such as carbonyl halide, carboxylic anhydride or carboxylic ester,]

and which are subsequently reacted [by known methods] with compounds of the general formula (VI) or salts thereof



in which

R^1 and R^3 are each as defined above in claim 1


in inert solvents,

and, if R^{11} carries one of the abovementioned protective groups, this is optionally removed by customary methods either in the hydrolysis to the acids (IV) \rightarrow (V) or after the reaction with the compounds of the general formula (VI),

or

[[B]] (B) if R^2 represents a saturated heterocycle which is attached directly to the imidazole [ring] via a ring via a nitrogen atom,

the above mentioned compounds of the general formula (II) are initially converted with compounds of the general formula (IIIa)




in which

A, D, E, G and L¹ are each as defined above in claim 1

and

Y represents halogen or mesylate, [preferably chlorine, bromine or mesylate,]

in inert solvents into the corresponding compounds of the formula (VII)



in which

Y, A, D, E, G, L¹, L² and T are each as defined above in claim 1,


which are reacted in a subsequent step with compounds of the general formula
(VIII)



in which

R¹² and R¹³ together with the nitrogen atom form a heterocycle according to the
definition of R² given in claim 1


to give compounds of the general formula (IX)



in which

A, D, E, G, L¹, L², R¹², R¹³ and T are each as defined above in claim 1,

which are, in the subsequent steps, converted as described under [[A]] (A) by hydrolysis into the corresponding carboxylic acids of the general formula (X)




in which

A, D, E, G, L¹, L², R¹² and R¹³ are each as defined above in claim 1

and these compounds are finally reacted with the compounds of the general formula (VI) according to known methods for preparing amides from carboxylic acids and amines and converted into the compounds of the general formula (I)

where the compounds of the general formula (I) obtained according to process variant [[A] or [B]] (A) or (B) can, if appropriate, subsequently be converted into the corresponding salts [by reaction with, for example, an acid].

9. (Amended) Compounds of the general formula (IV)




in which

A, D, E, G, L¹, L², R¹¹ and T are each as defined above in claim 1,

and their enantiomers and diastereomers and their respective salts.

10. (Amended) Compounds of the general formula (V)




in which

A, D, E, G, L¹, L² and R¹¹ are each as defined above in claim 1,

and their enantiomers and diastereomers and their respective salts.

11. (Amended) Compounds of the general formula (VII)




in which

A, D, E, G, L¹, L², Y and T are each as defined above in claim 1,

and their enantiomers and diastereomers and their respective salts.

12. (Amended) Compounds of the general formula (IX)




in which

A, D, E, G, L¹, L², R¹², R¹³ and T are each as defined above in claim 1,

and their enantiomers and diastereomers and their respective salts.

13. (Amended) Compounds of the general formula (X)



in which

A, D, E, G, L¹, L², R¹³, R¹² are each as defined above in claim 1.

and their enantiomers and diastereomers and their respective salts.

16. (Amended) [Medicaments], A pharmaceutical composition comprising a compound of the general formula (I) according to [any of] Claim[s] 1 [to 7] in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.
17. (Canceled) Compounds according to any of claims 1 to 7 for the prophylaxis and/or treatment of disorders in humans and animals.
18. (Canceled) Compounds according to any of Claims 1 to 7 for preparing medicaments for the prophylaxis and/or treatment of disorders in humans and animals.
19. (Canceled) Use of compounds according to any of Claims 1 to 7 for preparing medicaments for the prophylaxis and/or treatment of disorders in humans and animals.

20. (Canceled) Use of compounds according to any of Claims 1 to 7 for preparing medicaments for the treatment and/or prophylaxis of ischaemic disorders of the cardiovascular system.

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro



(43) Internationales Veröffentlichungsdatum
7. Dezember 2000 (07.12.2000)

Patente & Lizenz

27. April 2001

WO 00/73274 A3

not. ok

(51) Internationale Patentklassifikation: C07D 235/12 (INGA) (DE/DE): Am Soeren 13, D-22149 Hamburg (DE).
235/14, 235/30, 401/12, 471/04, A61K 31/4184, 31/4439, 31/4745, 31/496, 31/5377, A61P 9/00, C07D 235/24 (THIELEMANN, Wolfgang (DE/DE): Gartenstrasse 12,
213/56, C07C 237/20 (Wuppertal (DE): STEINHAGEN, Henning
(DE/DE): Egenstrasse 64, D-42113 Wuppertal (DE).

(21) Internationales Aktenzeichen: PCT/EP00/04431

(74) Gemeinsamer Vertreter: BAYER AKTIENGE-
SELLSCHAFT; D-51368 Leverkusen (DE).

(22) Internationales Anmeldedatum:
16. Mai 2000 (16.05.2000)

(81) Bestimmungsstaaten (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:
199 24 819.2 29. Mai 1999 (29.05.1999) DE

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von US): BAYER AKTIENGESELLSCHAFT (DE/DE);
D-51368 Leverkusen (DE).

(72) Erfinder; und

(75) Erfinder/Anmelder (nur für US): BISCHOFF, Erwin (DE/DE); Pahlkestrasse 73, D-42115 Wuppertal (DE).
LENSKY, Stephan (US/DE); Dornröschweg 10, D-51515 Kürten (DE). MÜLLER, Stephan-Nicholas (DE/DE); Rhönstrasse 19, D-42349 Wuppertal (DE).
PAULSEN, Holger (DE/DE); Pahlkestrasse 5, D-42115 Wuppertal (DE). KELDENICH, Jörg (DE/DE); Damschkeweg 49, D-42113 Wuppertal (DE). KRAHN, Thomas (DE/DE); Wienerstrasse 29, D-58135 Hagen (DE). SCHUMACHER, Joachim (DE/DE); Flüderstrasse 5, D-42109 Wuppertal (DE). JÄNICHEN, Jan

Veröffentlicht:


— Mit internationalem Recherchenbericht.

(88) Veröffentlichungsdatum des internationalen
Recherchenberichts: 19. April 2001

Zur Erklärung der Zweibuchstaben-Codes, und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.

(54) Title: SUBSTITUTED PHENYLCYCLOHEXANECARBOXYLIC ACID AMIDES AND THEIR USE AS ADENOSINE UPTAKE INHIBITORS.

(54) Bezeichnung: SUBSTITUIERTE PHENYLCYCLOHEXANECARBONSÄUREAMIDE UND IHRE VERWENDUNG ALS ADENOSINAUFNAHME-INHIBITOREN



(I)

(57) Abstract: The invention relates to substituted phenylcyclohexane carboxylic acid amides of the formula (I), to methods for producing said amides and to their use in medicaments, especially for treating cardiovascular diseases.

(57) Zusammenfassung: Die vorliegende Erfindung betrifft substituierte Phenylcyclohexanecarbonsäureamide der Formel (I), Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln, insbesondere zur Behandlung von kardiovaskulären Erkrankungen.

WO 00/73274 A3

Le 4 33 535

✖

Substituted phenylcyclohexanecarboxamides and their use as adenosine-uptake inhibitors


- 5 The present invention relates to substituted phenylcyclohexanecarboxamides, to a process for their preparation and to their use in medicaments, in particular for treating cardiovascular disorders, for example for the acute and chronic treatment of ischaemic disorders.
- 10 Adenosine is an endogenous effector with cell-protective activity, in particular under cell-damaging conditions with limited oxygen supply, such as, for example, in ischaemia. Adenosine is a highly effective vasodilator. It increases ischaemic "preconditioning" (R. Strasser, A. Vogt, W. Scharper, Z. Kardiologie 85, 1996, 79-89) and can promote the growth of collateral vessels. It is released under hypoxic
- 15 conditions, for example in the case of cardiac or peripheral occlusive diseases (W. Makarewicz "Purine and Pyrimidine Metabolism in Man", Plenum Press New York, 11, 1998, 351-357). Accordingly, adenosine protects against the effects of disorders caused by ischaemia, for example by increasing the coronary or peripheral circulation by vasodilation, by inhibiting platelet aggregation and by stimulating angiogenesis.
- 20 Compared to systemically administered adenosine, the adenosine-uptake inhibitors have the advantage of selectivity for ischaemia. Systemically administered adenosine causes a strong general, but frequently undesired, lowering of the blood pressure. The adenosine-uptake inhibitor increases the effect of the adenosine which is formed locally owing to the ischaemia and thus only dilates the vessels in the ischaemic
- 25 regions. Here, too, adenosine-uptake inhibitors increase the effects of adenosine and can be administered orally or intravenously for the prevention and therapy of ischaemic disorders, for example of coronary heart disease, of stable and unstable angina pectoris, of peripheral and arterial occlusive diseases, of thrombotic vascular occlusion, myocardial infarction and reperfusion damage. Moreover, owing to their
- 30 potential to increase angiogenesis, they are particularly suitable for a permanent therapy of all occlusive diseases.

Adenosine-uptake inhibitors can also be used for potentiating the effect of nucleobase, nucleoside or nucleotide antimetabolites in the chemotherapeutical

35 treatment of cancer and in antiviral (for example HIV) chemotherapy.

EP-A-0 611 767 and EP-A-725 064 disclose phenylcyclohexylcarboxamides which can be used for the treatment of atherosclerosis or restenosis.

The present invention relates to compounds of the general formula (I)



in which

A, D, E and G are identical or different and represent CH groups or nitrogen atoms,

L¹ and L² are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy or (C₁-C₆)-alkoxycarbonyl,

R¹ represents the CH₂-OH group, or
represents a radical of the formula CO-NR⁴R⁵,

in which

R⁴ and R⁵ are identical or different and each represents hydrogen or (C₁-C₆)-alkyl,

R² represents (C₃-C₈)-cycloalkyl,
represents (C₁-C₈)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR⁶,
represents a 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or
represents a 4- to 8-membered saturated heterocycle which contains a radical of the formula NR⁷ and optionally additionally one nitrogen, oxygen or sulphur atom,

5 where (C₃-C₈)-cycloalkyl, (C₁-C₈)-alkyl which is optionally interrupted by an oxygen or sulphur atom, the 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom and optionally (C₁-C₈)-alkyl which is interrupted by a radical NR⁶ and optionally the 4- to 8-membered saturated heterocycle which contains a radical of the formula NR⁷ and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula -NR⁸R⁹

10 in which

R⁶ and R⁷ are identical or different and each represents hydrogen, (C₁-C₆)-alkyl, hydroxy-(C₁-C₆)-alkyl or (C₃-C₇)-cycloalkyl,

15 R⁸ and R⁹ are identical or different and each represents hydrogen, (C₁-C₆)-alkyl or (C₃-C₇)-cycloalkyl,

or

20 R⁸ and R⁹ together with the nitrogen atom form a 4- to 8-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR¹⁰,

in which


25 R¹⁰ represents hydrogen, (C₁-C₆)-alkyl or (C₃-C₇)-cycloalkyl,

and

30 R³ represents a phenyl, naphthyl, pyrimidinyl, pyridyl, furyl or thienyl ring, where the rings are optionally mono- or polysubstituted by radicals selected from the group consisting of halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy and (C₁-C₆)-alkoxycarbonyl,

35 and their enantiomers and diastereomers and their respective salts, hydrates and, if appropriate, their prodrugs.

Among these, preference is given to compounds of the general formula (I) having the stereochemistry of the general formula (Ia) below



- 5 where the substituents R^1 , R^2 , R^3 , L^1 and L^2 and the radicals A, D, E and G are as defined above.

Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids
 10 or sulphonic acids. Particular preference is given, for example, to salts with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.

15 Depending on the substitution pattern, the compounds according to the invention can exist in stereoisomeric forms which either are like image and mirror image (enantiomers) or are not like image and mirror image (diastereomers). The invention relates both to the enantiomers or diastereomers and to their respective mixtures. The
 20 racemic forms, like the diastereomers, can be separated in a known manner into the stereoisomerically uniform components.

According to the invention "hydrates" refer to those forms of the compounds of the above general formula (I) which, in the solid or liquid state, form a molecular
 25 compound (solvate) by hydration with water. In the hydrates the water molecules are added via secondary valence bonds effected by intermolecular forces - in particular hydrogen bridge bonds. Solid hydrates contain water in the form of so-called water of crystallization in stoichiometric ratios, although the bonding states of the water molecules do not necessarily have to be the same. Examples of hydrates are sesqui-

hydrates, monohydrates, dihydrates or trihydrates. Possible hydrates can also be those of salts of the compounds according to the invention.

5 According to the invention, “prodrugs” are forms of the compounds of the general formula (I) or (Ia) above, which for their part can be biologically active or inactive, but which can be converted into the corresponding biologically active form (for example metabolically, solvolytically or in another way).

10 Examples of such “prodrugs” are, for example in the case that the above radical R^2 represents (C_3-C_8) -cycloalkyl, (C_1-C_8) -alkyl or a 4- to 8-membered saturated heterocycle, in each case substituted by one or more hydroxyl groups, compounds which can generate this/these hydroxyl group(s) metabolically, solvolytically or in another manner, for example esters, in particular amino acid esters (for example glycine esters, β -alanine esters, N-aminoethylglycine esters, etc.), phosphates, 15 acetals, semiacetals, glucuronates, and the like.

(C_1-C_8) -Alkyl, (C_1-C_6) -alkyl etc., represent a straight-chain or branched alkyl radical having 1 to 8 or 1 to 6 carbon atoms. Examples which may be mentioned are: methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl. Preference is given to a 20 straight-chain or branched alkyl radical having 1 to 4 carbon atoms (C_1-C_4). Particular preference is given to a straight-chain or branched alkyl radical having 1 to 3 carbon atoms (C_1-C_3).

(C_1-C_8) -Alkyl, (C_1-C_6) -alkyl etc., which is interrupted by an oxygen or sulphur atom and which is substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$ represent, for example, 1,3-dihydroxy-prop-2-oxy-methyl, 25 2-hydroxy-ethoxy-methyl, 2-hydroxy-prop-1-oxy-methyl, 3-hydroxy-prop-1-oxy-methyl, morpholin-4-yl-methyl, piperidin-1-yl-methyl, 2-amino-ethyl, 2-dimethyl-amino-ethyl or diethylamino-methyl.

30 (C_1-C_8) -Alkyl, (C_1-C_6) -alkyl etc., which is interrupted by a radical NR^6 and which is optionally substituted by one to three hydroxyl groups and/or by a radical of the formula $-NR^8R^9$ represent, for example, N-(2-hydroxy-ethyl)-aminomethyl, N-(2-hydroxy-ethyl)-N-methyl-aminomethyl or N,N-bis-(2-hydroxy-ethyl)-aminomethyl.

5 Hydroxy-(C₁-C₆)-alkyl or hydroxy-(C₁-C₄)-alkyl represents a straight-chain or branched alkyl radical having 1 to 6 or 1 to 4 carbon atoms. Examples which may be mentioned are: hydroxymethyl, 2-hydroxy-ethyl, 2-hydroxy-prop-1-yl, 3-hydroxy-prop-1-yl, 3-hydroxy-prop-2-yl, 2-hydroxy-but-1-yl, 5-hydroxy-pent-1-yl and 6-hydroxy-hex-1-yl. Preference is given to 2-hydroxy-ethyl.

10 (C₁-C₆)-Alkoxy represents a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms. Examples which may be mentioned are: methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy. Preference is given to a straight-chain or branched alkoxy radical having 1 to 4 carbon atoms (C₁-C₄). Particular preference is given to a straight-chain or branched alkoxy radical having 1 to 3 carbon atoms (C₁-C₃).

15 (C₁-C₆)-Alkoxycarbonyl represents a straight-chain or branched alkoxycarbonyl radical having 1 to 6 carbon atoms. Examples which may be mentioned are: methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl. Preference is given to a straight-chain or branched alkoxycarbonyl radical having 1 to 4 carbon atoms (C₁-C₄). Particular preference is
20 given to a straight-chain or branched alkoxycarbonyl radical having 1 to 3 carbon atoms (C₁-C₃).


25 (C₃-C₈)-Cycloalkyl, (C₃-C₇)-cycloalkyl etc., represent, in the context of the invention, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. Cyclopropyl, cyclopentyl and cyclohexyl may be mentioned as being preferred.

30 Halogen in the context of the invention generally represents fluorine, chlorine, bromine and iodine. Preference is given to fluorine, chlorine and bromine. Particular preference is given to fluorine and chlorine.


In the context of the invention, a 4- to 8-membered (preferably 5- to 7-membered) saturated heterocycle which is attached via a nitrogen atom and which optionally contains a further oxygen or sulphur atom represents, for example, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl or 1*H*-hexahydroazepin-1-yl.

In the context of the invention, a 4- to 8-membered (preferably 5- to 7-membered) saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom represents, for example, pyrrolidin-2-yl, 1-methylpyrrolidin-2-yl, pyrrolidin-3-yl, pyrazolidin-1-yl, piperidin-2-yl, 1-isopropyl-piperidin-3-yl, morpholin-2-yl, 4-cyclohexyl-piperazin-1-yl, thiomorpholin-3-yl, 1-ethyl-1H-hexahydroazepin-3-yl or 4-methyl-1H-hexahydro-1,4-diazepin-1-yl. This heterocycle can be attached to the imidazole ring via a ring carbon atom or a ring nitrogen atom.


The compounds according to the invention can be present in eight different configurations, and preference is given to the four different configurations (A) to (D) below:




(A)



(B)



(C)



(D)

Very particular preference is given to the configuration (D).

Preference is also given to compounds of the general formula (I) in which R^1 represents a radical of the formula $CO-NR^4R^5$ where R^4 and R^5 have the meaning given above and the other radicals are as defined above.

- 5 Particular preference is given to compounds of the general formula (I) according to the invention

where

- 10 A, D, E and G each represent the CH group,

or one of the radicals A, D, E and G represents a nitrogen atom and the others each represent the CH group,

- 15 L^1 and L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, fluorine, chlorine, cyano, trifluoromethyl and trifluoromethoxy,

- R^1 represents the $-CH_2-OH$ group, or
20 represents a radical of the formula $-CO-NR^4R^5$,

in which

- R^4 and R^5 are identical or different and each represents hydrogen or (C_1-C_3) -alkyl,
25

- R^2 represents (C_3-C_7) -cycloalkyl,
represents (C_1-C_6) -alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR^6 ,
30 represents a 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or
represents a 5- to 7-membered saturated heterocycle which contains a radical of the formula NR^7 and optionally additionally one nitrogen, oxygen or sulphur atom,
35

where (C₃-C₇)-cycloalkyl, (C₁-C₆)-alkyl which is optionally interrupted by an oxygen or sulphur atom, the 5- to 7-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains one further oxygen or sulphur atom and optionally (C₁-C₆)-alkyl which is interrupted by a radical NR⁶ and optionally the 5- to 7-membered saturated heterocycle which contains a radical of the formula NR⁷ and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by one hydroxyl group and/or by a radical of the formula -NR⁸R⁹,

in which

R⁶ and R⁷ are identical or different and each represents hydrogen, (C₁-C₄)-alkyl, hydroxy-(C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

R⁸ and R⁹ are identical or different and each represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

or

R⁸ and R⁹ together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR¹⁰,

in which

R¹⁰ represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

and

R³ represents a phenyl, pyridyl or thienyl ring which is optionally mono- or polysubstituted by radicals selected from the group consisting of fluorine, chlorine, cyano, trifluoromethyl and trifluoromethoxy,

and to their enantiomers and diastereomers and their respective salts, hydrates and, if appropriate, their prodrugs.

Very particular preference is given to compounds of the general formula (I) where

A, D and E each represent the CH group,

G represents a nitrogen atom or represents the CH group,

L^1 and L^2 each represent hydrogen,

R^1 represents a radical of the formula $-CO-NR^4R^5$,

in which

R^4 and R^5 each represent hydrogen.

R² represents (C₁-C₄)-alkyl which is optionally interrupted by an oxygen atom, or represents a 4-R⁷-piperazin-1-yl radical

where (C₁-C₄)-alkyl, which is optionally interrupted by an oxygen atom, is substituted by a hydroxyl group or by a radical of the formula -NR⁸R⁹,

in which

R⁷ represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

R⁸ and R⁹ are identical or different and each represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

or


R⁸ and R⁹ together with the nitrogen atom form a morpholine radical,

and

R³ represents a phenyl or pyridyl radical which may optionally be mono- or polysubstituted by fluorine,

and to their enantiomers and diastereomers and their respective salts, hydrates and, if appropriate, their prodrugs.

- 5 Very particular preference is also given to compounds of the general formula (Ib) below



in which

10

R^1 represents a group $-C(O)-NH_2$,

R^2 represents (C_1-C_3) -alkyl which is substituted at the terminal C atom by a hydroxyl group,

15

R^3 represents a phenyl ring which is optionally substituted in the para position by fluorine,

or

20


represents a pyridyl radical,

and to their diastereomers and their respective salts, hydrates and, if appropriate, their prodrugs.


25

Very particular preference is also given to the compounds of the general formula (I) with the following structures:


(*S*)-*N*-{[(1*R*,2*R*)-2-{4-{[2-hydroxymethyl]-1*H*-benzimidazol-1-yl]methyl}-phenyl]-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:




(*S*)-*N*-{[(1*R*,2*R*)-2-{4-{[2-(2-hydroxyethyl)-1*H*-benzimidazol-1-yl]methyl}-phenyl]-cyclohex-1-yl]carbonyl}-phenylglycinamide:




(*S*)-*N*-{[(1*R*,2*R*)-2-{4-{[2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl]methyl}-phenyl]-cyclohex-1-yl]carbonyl}-(3-pyridyl)glycinamide:



(*S*)-*N*-{[(1*R*,2*R*)-2-{4-{2-[2-(morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl}-phenyl]-cyclohex-1-yl]carbonyl}-phenylglycinamide:




(S)-N-{{[(1R,2R)-2-{4-[[2-(3-hydroxypropyl)-1H-benzimidazol-1-yl]methyl]-phenyl]-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:



and to their salts, hydrates and, if appropriate, their prodrugs.

- 5 Among these, very particular preference is given to (S)-N-{{[(1R,2R)-2-{4-[[2-(3-hydroxypropyl)-1H-benzimidazol-1-yl]methyl]phenyl]-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:




and to its salts, hydrates and, if appropriate, its prodrugs.

10

Moreover, processes for preparing the compounds of the general formula (I) according to the invention have been found where:

[A] compounds of the general formula (II)


15



in which

R^{11} , A, D, E, G, L^1 , L^2 and T are each as defined above,

5 which are converted in a subsequent step using acids or bases into the corresponding
carboxylic acids of the general formula (V)



in which


10

R^{11} , A , D , E , G , L^1 and L^2 are each as defined above,

which are, if appropriate, activated, in particular by conversion into a corresponding carboxylic acid derivative, such as carbonyl halide, carboxylic anhydride or carboxylic ester,

15

and which are subsequently reacted by known methods with compounds of the general formula (VI) or salts thereof



20

in which

R^1 and R^3 are each as defined above


25 in inert solvents,

and, if R^{II} carries one of the abovementioned protective groups, this is optionally removed by customary methods either in the hydrolysis to the acids (IV) \rightarrow (V) or after reaction with the compounds of the general formula (VI),

5 or

[B] if R^2 represents a saturated heterocycle which is attached directly to the imidazole ring via a nitrogen atom,

10 the abovementioned compounds of the general formula (II) are initially converted with compounds of the general formula (IIIa)



in which

15


A, D, E, G and L^1 are each as defined above

and

20

Y represents halogen or mesylate, preferably chlorine, bromine or mesylate,

in inert solvents into the corresponding compounds of the formula (VII)



25

in which

Y, A, D, E, G, L^1 , L^2 and T are each as defined above,


which are reacted in a subsequent step with compounds of the general formula (VIII)



5 in which

R^{12} and R^{13} together with the nitrogen atom form a heterocycle according to the definition of R^2


10 to give compounds of the general formula (IX)



in which

15 A, D, E, G, L^1 , L^2 , R^{12} , R^{13} and T are each as defined above,

which are, in the subsequent steps, converted as described under [A] by hydrolysis into the corresponding carboxylic acids of the general formula (X)



20

in which


A, D, E, G, L^1 , L^2 , R^{12} and R^{13} are each as defined above

and these compounds are finally reacted with the compounds of the general formula (VI) according to known methods customary for preparing amides from carboxylic acids and amines (for example, if appropriate, after an activation has been carried out, in particular by conversion into a corresponding activated carboxylic acid derivative, such as carbonyl halide, carboxylic anhydride or carboxylic ester) to give the compounds of the general formula (I).

The compounds of the general formula (I) obtained according to process variant [A] 10 or [B] can subsequently, if appropriate, be converted into the corresponding salts by reaction with, for example, an acid.


The compounds of the corresponding diastereomeric and enantiomeric forms are prepared correspondingly, either using enantiomerically or diastereomerically pure 15 starting materials or by separating the racemates formed afterwards using customary methods (for example resolution of racemates, chromatography over chiral columns and the like).

Thus, it is possible to prepare, for example, the compounds of the preferred
20 configuration of the general formula (Ia)




where the substituents R^1 , R^2 , R^3 , L^1 and L^2 and the radicals A, D, E and G are as defined above

by using, instead of the racemic compound of the general formula (VI), the enantiomerically pure compound of the general formula (VI a)



or salts thereof.

A very particularly preferred compound of the general formula (VI a) is (*S*)-(4-fluorophenyl)glycinamide





and its salts (for example the hydrochloride).

A compound of the general formula (VI a) which is likewise very particularly preferred is (*S*)-(3-pyridyl)glycinamide and its salts.


The processes according to the invention can be illustrated in an exemplary manner by the following formula schemes:

[A]





[B]



Suitable amino protective groups in the context of the invention are the customary amino protective groups used in peptide chemistry.

5 These preferably include: benzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl, vinyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, cyclohexoxycarbonyl, 1,1-dimethylethoxycarbonyl, adamantylcarbonyl, 10 phthaloyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-trichloro-tert-butoxycarbonyl, menthloxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, formyl, acetyl, propionyl, pivaloyl, 2-chloroacetyl, 2-bromoacetyl, 2,2,2-trifluoroacetyl, 2,2,2-trichloroacetyl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, phthalimido, isovaleroyl or benzyloxymethylene, 4-nitrobenzyl, 2,4-dinitrobenzyl or 4-nitrophenyl. A preferred protective group for primary amines is phthalimide. Preferred protective groups for secondary amines are benzyloxycarbonyl and tert-butoxycarbonyl.

20 The amino protective groups are removed in a manner known per se, for example under hydrogenolytic, acidic or basic conditions, preferably using acids, such as, for example, hydrochloric acid or trifluoroacetic acid, in inert solvents, such as ether, dioxane and methylene chloride.

25 A suitable hydroxyl protective group in the context of the definition given above is generally a protective group from the series: trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyl-dimethylsilyl, tert-butyldiphenylsilyl, dimethylhexylsilyl, trimethylsilylethoxycarbonyl, benzyl, triphenylmethyl (trityl), monomethoxytrityl (MMTr), dimethoxytrityl (DMTr), benzyloxycarbonyl, 2-nitrobenzyl, 4-nitrobenzyl, 2-nitrobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, tert-butyloxycarbonyl, 30 4-methoxybenzyl, 4-methoxybenzyloxycarbonyl, formyl, acetyl, trichloroacetyl, 2,2,2-trichloroethoxycarbonyl, 2,4-dimethoxybenzyl, 2,4-dimethoxybenzyloxycarbonyl, methoxymethyl, methylthiomethyl, methoxyethoxymethyl, [2-(trimethylsilyl)ethoxy]-methyl, 2-(methylthiomethoxy)ethoxycarbonyl, tetrahydropyranyl, benzoyl, N-succinimide, 4-methylbenzoyl, 4-nitrobenzoyl,

35

4-fluorobenzoyl, 4-chlorobenzoyl or 4-methoxybenzoyl. Preference is given to tert-butyltrimethylsilyl.

5 The hydroxyl-protective group is removed in a manner known per se, for example using acid or base, or by addition of tetrabutylammonium fluoride, or is carried out during the hydrolysis of the carboxylic acid.

10 Suitable solvents for the processes are customary organic solvents which do not change under the reaction conditions. These include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate, pyridine, dimethyl sulphoxide, dimethylformamide, N,N'-dimethylpropyleneurea (DMPU),
15 N-methylpyrrolidone (NMP), acetonitrile, acetone or nitromethane. It is also possible to use mixtures of the solvents mentioned. For the process [A] (II) + (III) \rightarrow (IV), preference is given to diethyl ether, tetrahydrofuran and dimethylformamide. Particular preference is given to dimethylformamide.

20 Suitable for use as bases in the process according to the invention are, in general, inorganic or organic bases. These preferably include alkali hydroxides, such as, for example, sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides, such as, for example, barium hydroxide, alkali metal carbonates, such as sodium carbonate, potassium carbonate or caesium carbonate, alkaline earth metal
25 carbonates, such as calcium carbonate, or alkali metal or alkaline earth metal alkoxides, such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium tert-butoxide, or organic amines (trialkyl(C₁-C₆)amines), such as triethylamine, or heterocycles, such as 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU),
30 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), pyridine, diaminopyridine, methylpiperidine or morpholine. It is also possible to use, as bases, alkali metals, such as sodium, or their hydrides, such as sodium hydride. Preference is given to sodium hydride, potassium carbonate, caesium carbonate, triethylamine, trimethylamine, pyridine, potassium tert-butoxide, DBU or DABCO. Very particularly preferred for
35 the step [A] (II) + (III) \rightarrow (IV) are sodium hydride and sodium hydroxide.

In general, the base is employed in an amount of from 0.05 mol to 10 mol, preferably from 1 mol to 2 mol, based on 1 mol of the compound of the formula (II).

The process (II) + (III) \rightarrow (IV) according to the invention is generally carried out in a temperature range from -20°C to $+100^{\circ}\text{C}$, in particular from -20°C to $+60^{\circ}\text{C}$, preferably from 0°C to $+60^{\circ}\text{C}$.

The process (II) + (III) \rightarrow (IV) according to the invention is generally carried out under atmospheric pressure. However, it is also possible to carry out the process under elevated pressure or under reduced pressure (for example in a range from 0.5 to 5 bar).

The hydrolysis of the carboxylic esters is carried out by customary methods by treating the esters in inert solvents with customary bases, the salts which are formed initially being converted by treatment with acid into the free carboxylic acids, or, in the case of the t-butyl esters, with acid.

20 Suitable bases for the hydrolysis are the customary inorganic bases. These preferably include alkali metal hydroxides or alkaline earth metal hydroxides, such as, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or barium hydroxide, or alkali metal carbonates, such as sodium carbonate or potassium carbonate or sodium bicarbonate. Particular preference is given to using sodium hydroxide or lithium hydroxide.

25 Suitable acids are, in general, trifluoroacetic acid, sulphuric acid, hydrogen chloride, hydrogen bromide and acetic acid, or mixture thereof, if appropriate with addition of water. Preference is given to hydrogen chloride or trifluoroacetic acid in the case of the tert-butyl esters and to hydrochloric acid in the case of the methyl esters.

Solvents which are suitable for the hydrolysis are water or the organic solvents customarily used for hydrolysis. These preferably include alcohols, such as methanol, ethanol, propanol, isopropanol or butanol, or ethers, such as tetrahydrofuran or dioxane, dimethylformamide, dichloromethane or dimethyl sulphoxide. It is also possible to use mixtures of the solvents mentioned. Preference is given to water/tetrahydrofuran and, in the case of the reaction with trifluoroacetic acid,

dichloromethane and, in the case of hydrogen chloride, tetrahydrofuran, diethyl ether, dioxane or water.

The hydrolysis is generally carried out in a temperature range from 0°C to +100°C.


In general, the hydrolysis is carried out at atmospheric pressure. However, it is also possible to operate under reduced pressure or under elevated pressure (for example from 0.5 to 5 bar).

When carrying out the hydrolyses, the base or the acid is generally employed in an amount of from 1 to 100 mol, preferably from 1.5 to 40 mol, based on 1 mol of the ester.

Preferred auxiliaries used for the amide formations are condensing agents. Preference is given here to using the customary condensing agents, such as carbodiimides, for example N,N'-diethyl-, N,N'-dipropyl-, N,N'-diisopropyl-, N,N'-dicyclohexyl-carbodiimide, N-(3-dimethylaminoisopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) or carbonyl compounds, such as carbonyldiimidazole, or 1,2-oxazolium compounds, such as 2-ethyl-5-phenyl-1,2-oxazolium-3-sulphate or 2-tert-butyl-5-methyl-isoxazolium perchlorate, or acylamino compounds, such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, or propanephosphonic acid anhydride, or isobutyl chloroformate, or bis-(2-oxo-3-oxazolidinyl)-phosphoryl chloride or benzotriazolyloxy-tri(dimethylamino)phosphonium hexafluorophosphate, or O-(benzotriazol-1-yl) N,N,N',N'-tetra-methyluronium hexafluorophosphate (HBTU) or O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium hexafluorophosphate (HATU) and, as bases, alkali metal carbonates, for example sodium carbonate or bicarbonate or potassium carbonate or bicarbonate, or organic bases, such as trialkylamines, for example triethylamine, N-ethylmorpholine, N-methylpiperidine or diisopropylethylamine. Particular preference is given to the combination of EDC, N-methylmorpholine and 1-hydroxybenzotriazole.

The compounds of the general formulae (II), (IIIa), (VI) and (VIII) are known or can be prepared by customary methods (cf. EP-A-0 725 061, EP-A-0 725 064).

Most of the compounds of the general formula (III) are novel, and they can be prepared, in the case that R¹¹ does not represent a heterocycle which is attached directly via N, by reacting compounds of the general formula (XI)



in which

A, D, E, G and L_1 are each as defined above

with compounds of the general formula (XII)



in which

R^{11} is as defined above

or, if appropriate, esters, lactones or other reactive precursors thereof (for example imido esters)

if appropriate with removal of the water of reaction, if appropriate in the presence of an acid, preferably PPA, HCl and p-TsOH (cf. also *J. Org. Chem.* **1941**, *6*, 25 ff. and *Bull. Soc. Chim. Fr.* **1991**, 128, 255-259)

and, in the case that R^{11} represents one of the radicals listed above under R^2 which optionally also carries a protective group, by converting compounds of the general formula (XI) initially by reaction with compounds of the general formula (XIII)




in which

R^{14} represents (C₁-C₈)-alkanediyl

or, if appropriate, esters, lactones or other reactive precursors thereof (for example imido esters)

5 into the compounds of the general formula (XIV)




in which

10

A, B, D, G, R^{14} and L^1 are each as defined above

in inert solvents,

15 subsequently substituting the hydroxyl group by halogen, mesylate or tosylate, thus producing the compounds of the general formula (XV)



20 in which

R^{14} , A, D, E, G and L^1 are each as defined above

and

25

Z represents halogen, mesylate or tosylate,

and reacting these with amines of the general formula (XVI)

30



in which

R⁸ and R⁹ are each as defined above

(cf. also *J. Am. Chem. Soc.* **1948**, 70, 3406; *J. Heterocycl. Chem.* **1969**, 759-60).

5

10

15

Solvents which are suitable for the process are customary organic solvents which do not change under the reaction conditions. These preferably include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate, pyridine, dimethyl sulphoxide, dimethylformamide, N,N'-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP), acetonitrile, acetone or nitromethane. It is also possible to use mixtures of the solvents mentioned. Preference is given to dichloromethane, tetrahydrofuran and dimethylformamide.

20

25

30

Bases suitable for use in the process according to the invention are, in general, inorganic or organic bases. These preferably include alkali metal hydroxides, such as, for example, sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides, such as, for example, barium hydroxide, alkali metal carbonates, such as sodium carbonate, potassium carbonate or caesium carbonate, alkaline earth metal carbonates, such as calcium carbonate, or alkali metal or alkaline earth metal alkoxides, such as sodium methoxide or potassium methoxide, sodium ethoxide or potassium ethoxide or potassium tert-butoxide, or organic amines (trialkyl-(C₁-C₆)amines) such as triethylamine, or heterocycles such as 1,4-diazabicyclo-[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), pyridine, diaminopyridine, methylpiperidine or morpholine. It is also possible to use, as bases, alkali metals, such as sodium, or their hydrides, such as sodium hydride. Preference is given to sodium hydride, potassium carbonate, triethylamine, trimethylamine, pyridine, potassium tert-butoxide, DBU or DABCO.

35

In general, the base is employed in an amount of from 0.05 mol to 10 mol, preferably from 1 mol to 2 mol, based on 1 mol of the compound of the formula (XV).

The process according to the invention is generally carried out in a temperature range of from -50°C to +100°C, preferably from -30°C to +60°C.

Test systems

1. Determination of the solubility

To determine the solubility, a precipitation method was used:

10 mg of the test substance are completely dissolved in 50 µl of DMSO (stock solution). 20 µl of this solution are added to 2000 µl of physiological saline. This solution, in turn, is shaken at 25°C in a Thermomixer Comfort (from Eppendorf) at 1400 rpm for 24 hours for equilibration.

The precipitated fractions of the test substance are centrifuged off using a Biofuge 15 from Heraeus at 14,000 rpm for 5 min. 1300 µl of the supernatant are once more centrifuged using a Microfuge from Beckmann at 45,000 rpm = 125,000 g.

10 μ l of this centrifugation supernatant are then diluted with 1000 μ l of DMSO, and this solution is measured by HPLC (Hewlett Packard 1090, method, gradient from 100% PBS buffer pH = 4 to 10% buffer/90% acetonitrile over a period of 15 min, column: RP18).

Using a calibration curve, the measured peak area of the HPLC measurement is converted into the substance concentration. For the calibration curve, 20 µl of the stock solution are diluted successively with DMSO such that 5 concentrations of 2.5 mg/l to 2000 mg/l result. These solutions are likewise measured by HPLC (see method above), and the peak areas are plotted as a function of the concentrations.

2. Inhibition of adenosine uptake in rabbit erythrocytes by the compounds according to the invention.

The capability of substances to influence the adenosine-uptake system is investigated by determining the inhibitory effect of the substances on functional adenosine uptake.

For the functional adenosine-uptake test, an erythrocyte preparation from rabbit blood is used. The blood is drawn intravenously using citrate (3 ml Monovette 9NC from Sarstedt) as anticoagulant. The blood is centrifuged at 3000 g for 5 min and the erythrocytes are suspended in 10 mM MOPS/0.9% NaCl solution pH 7.4. The suspension is diluted to one hundredth of the original blood volume. In each case

990 µl of the suspension are admixed with 10 µl of a suitable concentration of the substance to be investigated, and the mixture is incubated at 30°C for 5 min. 5 µl of a 4 mM adenosine solution are then added, and the mixture is incubated at 30°C for another 15 min. The samples are then centrifuged at 3000 g for 5 min and in each case 700 µl of the supernatant are admixed with 28 µl of 70% strength HClO₄, allowed to stand in an ice bath for 30 min and centrifuged at 16,000 g for 3 min, and 350 µl of the sample are neutralized using 30 µl of 5N NaOH. 50 µl of the sample are applied to a column (Waters Symmetry C18 5 µm 3.9x150 mm). A Spherisorb ODS II 5 µm 4.6 × 10 mm column is used as precolumn. The mobile phase used is a gradient of 50 mM KH₂PO₄/5 mM tributylamine pH 7 (mobile phase A) and a mixture of mobile phase A/methanol 1/1 (mobile phase B). The gradient is from 10-40% B, at a flow rate of 0.5 ml/min. The adenosine which is present is quantified by its absorption at 260 nm, as are the hypoxanthine and inosine formed. The IC₅₀ is the concentration of active compound at which, 15 min after addition of adenosine, 50% of the adenosine concentration originally employed is still present.

Using this test, the IC₅₀ value determined for Example 3 was 15 nM, that for Example 8 was 20 nM, that for Example 10 was 25 nM and that for Example 16 was 10 nM.

3. In vivo test model for testing "adenosine-reuptake inhibitors"

Adult FBI (Foxhound-Beagle-Irish-Setter) dogs (20-30 kg) are initially anaesthetized using a combination of trapanal 500 mg and alloferin 55 mg. Anaesthesia is maintained by infusion of a mixture of fentanyl 0.072 mg/kg, alloferin 0.02 mg/kg and dihydrobenzpyridyl 0.25 mg/kg x min. The animals are intubated and ventilated with a mixture of O₂/N₂O 1/5 using an Engström ventilation pump at 16 breaths per min and a volume of 18-24 ml/kg. The body temperature is maintained at 38°C ± 0.1°C. Arterial blood pressure is measured via a catheter in the femoral artery. Thoracotomy is carried out on the left side at the fifth intercostal space. The lung is pushed back and fixed and a cut is made in the pericardium. A proximal section of the LAD distally to the first diagonal branch is exposed and a calibrated electromagnetic flow sensor (Gould Statham, model SP7515) is placed around the vessel and attached to a flow meter (Statham, model SP-2202). Distally to the flow sensor, a mechanic occluder is attached such that there are no branches in between flow sensor and occluder.

Using a catheter in the femoral vein, blood samples are taken and substances administered. A peripheral ECG is recorded using needles which are fixed subcutaneously. A microtip pressure manometer (Millar model PC-350) is pushed through the left atrium to measure the pressure in the left ventricle. Measurement of the heart frequency is triggered by the R wave of the ECG. During the entire experiment, the haemodynamic parameters and coronary flow are recorded using a multi-event recorder.

A four-minute occlusion causes reactive hyperaemia. The difference between the coronary flow under control conditions and the maximum flow during the reactive hyperaemia is measured. The time which is required to achieve half of this maximum flow in the drop is a suitable parameter to assess the reactive hyperaemia.

After a stabilization period of one hour, the experiment is started with a four-minute occlusion. Thirty minutes later, the substance is administered (i.v.) which is, after two minutes, followed by re-occlusion. The reactive hyperaemia after verum and placebo is compared.

4. Mouse angiogenesis model

To test the effect of adenosine-reuptake inhibitors on collateralization and neovascularization a mouse model for angiogenesis was developed. To this end, a femoral artery of the mouse is ligated at the upper end of the thigh. This induces chronic ischaemia of the hind leg in question. The other hind leg serves as individual control. To exclude residual flow through the ligated vessel, two ligatures are applied, and the vessel is cut in between. A few days after this operation, the treatment is started.

As a measurement parameter during the ongoing experiment, the temperatures of the paws of the two hind legs are measured. Owing to poorer circulation, the ischaemic hind leg has a lower absolute temperature. In each case, the temperature difference between the paws of the hind legs is calculated. This individual temperature difference is determined in different treatment groups as a function of the dose and in comparison with an untreated control. In this model, adenosine-reuptake inhibitors

significantly improve the circulation of the ischaemic hind leg in comparison with the corresponding controls.

5 The novel active compounds can be converted in a known manner into the customary formulations, such as tablets, sugar-coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable carriers or solvents. In this connection, the therapeutically active compound should in each case be present in a concentration of approximately 0.5 to 90% by weight of the total mixture, i.e. in amounts which are sufficient in order to achieve
10 the dosage range indicated.

The formulations are prepared, for example, by extending the active compounds using solvents and/or carriers, if appropriate using emulsifiers and/or dispersants, where, for example, if the diluent used is water, organic solvents can optionally be
15 used as auxiliary solvents.

Administration is carried out in a conventional manner, preferably orally, transdermally, parenterally, perlingually, intravenously; particularly preferably orally or intravenously.

20 In general, it has proven advantageous in the case of intravenous administration to administer amounts of approximately 0.0001 to 10 mg/kg, preferably approximately 0.003 to 1 mg/kg, of body weight, to achieve effective results. In the case of oral administration, 0.1 to 20 mg/kg, preferably 0.3- 3 mg/kg, of body weight are
25 employed.

In spite of this, if appropriate it may be necessary to depart from the amounts mentioned, namely depending on the body weight or on the type of administration route, on the individual response towards the medicament, the manner of its
30 formulation and the time or interval at which administration takes place. Thus, in some cases it may be adequate to manage with less than the abovementioned minimum amount, while in other cases the upper limit mentioned has to be exceeded. It may be advisable to divide this amount into a number of individual doses over the
35 course of the day.

Starting materials

The following abbreviations for solvents are used in the examples:

DMF = N,N-dimethylformamide

5 DMSO = dimethyl sulphoxide


PPA = polyphosphoric acid

TFA = trifluoroacetic acid

THF = tetrahydrofuran

10 **Example 1A**

(1*R*, 2*R*)-2-(4-Methyl-phenyl)-cyclohexane-1-carboxylic acid




15 Racemic (1*R**, 2*R**)-2-(4-methyl-phenyl)-cyclohexane-1-carboxylic acid was prepared analogously to the process described in US-A-5,395,840, column 16. The resulting racemic material was separated into the enantiomers using the following procedure:

20 The racemic acid (415 g; 1.9 mol) and triethylamine (96.2 g; 0.95 mol; 131.8 ml) were suspended in a mixture of THF (2.7 l) and water (5.3 l). At 60°C, S-(-)-phenylethylamine (115.2 g; 0.95 mol) was added dropwise, resulting in a precipitate being formed. The mixture was stirred at 60°C for 2 h and then cooled using an ice bath. This precipitate was filtered off with suction, giving predominantly the phenylethylamine salt of the (1*S*, 2*S*)-enantiomer. The filtrate was acidified using
25 conc. HCl and extracted twice using dichloromethane. The combined extracts were dried over sodium sulphate and concentrated. Yield: 202.4 g (28%) of a mixture of enantiomers enriched with the (1*R*, 2*R*)-isomer.

This mixture was treated with R-(+)-phenylethylamine as described above to precipitate the desired enantiomer as a salt. The colourless crystals were filtered off with suction and recrystallized from acetonitrile/methanol (6:1). X-ray analysis of these crystals confirmed the (1*R*, 2*R*)-configuration. Yield 136.9 g (46%). Work-up (see above) gave 89 g of (1*R*, 2*R*)-2-(4-methylphenyl)-cyclohexane-1-carboxylic acid.


Example 2A

10 **tert-Butyl (1*R*, 2*R*)-2-(4-bromomethyl-phenyl)-cyclohexane-1-carboxylate:**



The intermediate was prepared analogously to the procedure for the racemate (US-A-5,395,840, column 17). For purification, the resulting mixture was stirred
15 with diethyl ether.

Example 3A

2-(2-Phthalimidylethyl)-1*H*-benzimidazole


20

2-Aminoethylbenzimidazole dihydrochloride (*Bull. Soc. Chim. Fr.* **1991**, 128, 255-259; 2.34 g, 10 mmol), phthalic anhydride (1.63 g, 11 mmol) and triethylamine (2.79 ml, 20 mmol) in chloroform (25 ml) were heated at reflux overnight, and the

mixture was then cooled to room temperature, diluted with ethyl acetate and filtered off. The filtrate was washed with saturated sodium carbonate solution, buffer (pH = 7) and saturated sodium chloride solution and dried over sodium sulphate. Chromatography (dichloromethane:methanol 10:1, R_f = 0.4) gave 2.08 g of 2-(2-phthalimidylethyl)-benzimidazole (71.4% of theory) as a colourless foam. MS (DCI, NH_3) = 292 ($\text{M}+\text{H}^+$). $^1\text{H-NMR}$ ($\text{DMSO-}d_6$): 3.15 (2 H, t); 4.0 (2 H, t); 7.05-7.2 (2 H, m); 7.4-7.5 (2 H, m); 7.8-7.9 (4 H, m); 12.4 (1 H, br s).

The remainder of the synthesis is carried out following the general procedures A, B and C as mentioned below, and in a last step, the phthalimide group is cleaved off as described below.

Example 4A


2-(2-Hydroxyethoxymethyl)-pyrido[2,3-*d*]-1*H*-imidazole

1,4-Dioxan-2-one (6.13 g, 60 mmol) and 2,3-diaminopyridine (5.46 g, 50 mmol) in mesitylene (100 ml) were heated at reflux in a Dean-Stark separator for 10 h. After cooling, mesitylene was decanted off and the residue was purified by silica gel chromatography (dichloromethane:methanol 9:1) (yield: 8.47 g, 87% of theory).

MS(DCI)=194 (M+H, 100%); ¹H-NMR (DMSO-d₆): 3.78 (2 H, m); 3.89 (2 H, m); 4.91 (2 H, s); 5.3 (1 H, s); 7.18 (1 H, dd); 7.95 (1 H, d); 8.43 (1 H, dd); 12.7 (1 H, br s).

Example 5A


2-[2-(*tert*-Butyldimethylsilyloxy)ethoxymethyl]-pyrido[2,3- *d*]-1*H*-imidazole



8.4 g (43.48 mmol) of 2-(2-hydroxyethoxymethyl)-(pyrido-[2,3-d]-1*H*-imidazole) and 4.84 g (47.82 mmol) of triethylamine were dissolved in 120 ml of DMF and admixed with 7.21 g (47.8 mmol) of TBDMS chloride, the mixture warming to about 40°C. Stirring at room temperature was continued for 2 h, and the mixture was then poured into water, giving the product in crystalline form. The product was filtered off with suction, washed with a little water and dried under high vacuum. ¹H-NMR (DMSO-d₆): 0.02 (6 H, s); 0.83 (9 H, s); 3.52 (2 H, t); 3.75 (2 H, t); 4.73 (2 H, s); (1 H, dd); 7.90 (1 H, dd); 8.43 (1 H, dd); 12.9 (1 H, br s).

Example 6A


2- *tert*-Butyldimethylsilyloxymethyl-1*H*-benzimidazole:



At room temperature, triethylamine (2.27 ml, 16.3 mmol) and TBDMS chloride (1.65 g, 10.95 mmol) were added to a solution of 2-hydroxymethylbenzimidazole (1.48 g, 9.95 mmol) in DMF (30 ml). After 3.5 h, the reaction was terminated by addition of water, the mixture was extracted with diethyl ether and the organic phase

- 38 -


was dried over sodium sulphate. Chromatography (silica gel, cyclohexane:ethyl acetate 2:1, $R_f=0.35$) gave 2.52 g of 2-*tert*-butyldimethylsilyloxymethyl-benzimidazole (97% of theory) as a brownish powder. MS (DCI, NH_3) = 263 ($\text{M}+\text{H}^+$). $^1\text{H-NMR}$ (DMSO-d_6): 0.00 (6 H, s); 0.80 (9 H, s); 4.75 (2 H, s); 7.0-7.1 (2 H, m); 7.4-7.5 (2 H, m); 12.15 (1 H, br s).

Example 7A**2-(2-Hydroxyethoxymethyl)-1H-benzimidazole:**

10

Using a Dean-Stark separator, 1,4-dioxan-2-one (2.04 g, 20 mmol) and 1/2-diaminobenzene (2.16 g, 20 mmol) were heated under reflux in mesitylene (150 ml) for 10 h. The crystals formed on cooling were then filtered off with suction (2.94 g, 77% of theory). R_f (dichloromethane:methanol 10:1) = 0.45, MS (EI) = 192 (M^+ , 20%), 148 (20%), 147 (40%), 132 (100%), $^1\text{H-NMR}$ (DMSO-d_6): 3.6 (4 H, s); 4.65 (1 H, s); 4.7 (2 H, s); 7.1-7.2 (2 H, m); 7.45 (1 H, d); 7.55 (1 H, d); 12.4 (1 H, br s).

15

Example 8A**2-(3-{[*tert*-Butyl(dimethyl)silyl]oxy}propyl)-1H-benzimidazole**

20


The silylation of 2-(3-hydroxypropyl)-1*H*-benzimidazole was carried out analogously to the process described in Example 6A.


To this end, tert-butyldimethylsilyl chloride (TBDMSCl) (14.68 g, 97.37 mmol) was added a little at a time to a solution of 2-(3-hydroxypropyl)-benzimidazole (15.60 g, 88.52 mmol) in DMF (265 ml) and triethylamine (20.27 ml, 145.41 mmol). The mixture was stirred at RT overnight and then admixed with water (800 ml) and extracted with diethyl ether. The organic phase was dried over sodium sulphate and chromatographed over silica gel (mobile phase: cyclohexane/ethyl acetate = 6:1), giving 25 g (97%) of colourless crystals.
MS (DCI): 291 (M+H)⁺

¹H-NMR (CDCl₃): 0.12 (6 H, s); 0.92 (9 H, s); 2.08 (2 H, m); 3.10 (2 H, t); 3.80 (2 H, t); 7.20 (2 H, m); 7.52 (2 H, br. s).

Example 9A

(S)- (4-Fluorophenyl)glycinamide hydrochloride



Route 1:**a) (S)-N-(tert-Butoxycarbonyl)-(4-fluorophenyl)glycine**

5


(S)-(4-Fluorophenyl)glycine (35 g, 207 mmol) and sodium carbonate (54.8 g, 517 mmol) were initially charged in water (150 ml) and tetrahydrofuran (75 ml), and di-tert-butyl pyrocarbonate (Boc anhydride) (52.3 ml, 228 mmol) was added dropwise at room temperature. The reaction mixture was stirred overnight at RT. Using 5N hydrochloric acid, the reaction solution was adjusted to pH 3 and extracted with dichloromethane and water, and the aqueous phase was re-extracted twice with dichloromethane. The combined organic phases were dried over sodium sulphate and filtered, and the solvent was removed under reduced pressure. The product (54.2 g, 97% of theory) was reacted without any further purification.

MS (ESI)= 561 (2M+Na⁺, 40 %), 292 (M+Na⁺, 100 %), 236 (40 %), 214 (70 %), 153 (95 %).

15

¹H-NMR (DMSO-d₆): 1.38 (9 H, s); 5.11 (1 H, br. d); 7.12-7.21 (2 H, m); 7.39-7.47 (2 H, m); 7.56 (1 H, br. d); 12.78 (1 H, br. s).

20

b) (S)-N-(tert-Butoxycarbonyl)-(4-fluorophenyl)glycinamide

25

Under argon, the product from Example 9A a) (54.2 g, 201 mmol) was dissolved in tetrahydrofuran (600 ml), the mixture was cooled to - 15°C (internal temperature) and triethylamine (201 mmol, 28.1 ml) and isobutyl chloroformate (201 mmol,

- 41 -


26.1 ml) were added successively over a period of 5 min. The mixture was stirred at -15°C for 25 min, after which ammonia in methanol (126 ml of a 2N solution) was added, and the reaction mixture was stirred at this temperature for 30 min. The mixture was filtered and the filter residue was dissolved in dichloromethane and extracted with water. The organic phase was washed twice with sodium carbonate solution and dried over sodium sulphate, and the solvent was removed under reduced pressure. The residue was admixed with petroleum ether and crystallized at 4°C overnight. After filtration and rinsing with petroleum ether, the product (33.9 g, 63% of theory) was isolated as a solid.

R_f (methanol : dichloromethane = 1:10) = 0.46

MS (DCI/NH₃) = 269 (M+H⁺, 60 %), 169 (100 %).

¹H-NMR (DMSO-d₆): 1.37 (9 H, s); 5.09 (1 H, br. d); 7.1-7.3 (4 H, m); 7.37-7.51 (2 H, m); 7.57 (1 H, br. s).

c) (S)- (4-Fluorophenyl)glycinamide hydrochloride




The product from Example 9A b) (33.8 g, 126 mmol) was dissolved in a solution of hydrogen chloride in 1,4-dioxane (250 ml of a 4N solution) and 1,4-dioxane (100 ml), and the mixture was stirred at RT for 2 h. The resulting precipitate was filtered off with suction, washed with diethyl ether and, after drying under reduced pressure, triturated once more with diethyl ether, filtered off with suction and dried under reduced pressure. The product was isolated as a colourless solid (24.3 g, 94.4% of theory) of an enantiomeric purity > 99% ee.


MS (DCI/NH₃) = 337 [2(M-HCl)+H⁺, 20%], 169 [(M-HCl)+H⁺, 100%].

¹H-NMR (DMSO-d₆): 4.97 (1 H, s); 7.2-7.4 (2 H, m); 7.5-7.7 (2 H, m); 8.13 (1 H, s); 8.80 (3 H, s).

Route 2:


Alternatively to route 1, it was possible to prepare the compound from Example 9A c), i.e. (S)-(4-fluorophenyl)glycinamide hydrochloride, by the following route:



i) ***rac*-(2-Benzylamino)-2-(4-fluorophenyl)acetonitrile [*rac*-(3)]*****rac*-(3)**

- 5 4- Fluorobenzaldehyde is initially reacted with benzylamine in a cyanide solution in acetic acid in a so-called Strecker reaction, which is one of the standard reactions in amino acid syntheses (see, for example, the four literature references: 1.) Hassan, N.A., Bayer, E., Jochims, J.C., *J.Chem.Soc. Perkin 1* **1998**, 3747-3757; 2.) Georgiadis, M.P., Haroutounian, S.A., *Synth. Comm.* **1989**, 616; 3.) Alabaster, R.J., Gibson, A.W., Johnson, S.A., Edwards, J.S., Cottrell, I.F., *Tetrahedron Asymmetry* **1997**, *8*, 447-450, quoted therein: Alabaster, R.J.; Cottrell, I.F.; Gibson, A.W.; Johnson, S.A.: UK Patent Appl. 9511031.8; 4.) Inaba, T., Fujita, M., Ogura, K., *J.Org.Chem.* **1991**, *56*, 1274-1279).
- 10
- 15 Under the conditions described in literature reference 1.) (Hassan, N.A., Bayer, E., Jochims, J.C., *J.Chem.Soc. Perkin 1* **1998**, 3747-3757), the racemic (2-benzylamino)-2-(4-fluorophenyl)acetonitrile [*rac*-(3)] was prepared in a yield of 85%.


ii) **(S)- Benzyl[cyano(4-fluorophenyl)methyl]ammonium (R)-amygdalate [(S,R)-(4)]**



5 The racemic product from Example 9A i) was then dissolved in ethanol and admixed with (R)-mandelic acid to isolate, in a kinetic racemate separation, the diastereomerically pure (S)-benzyl[cyano(4-fluorophenyl)methyl]ammonium (R)-amygdalate (see literature reference 1.) above, *J.Chem.Soc. Perkin 1 1998*, 3747-3757). 63% of the diastereomerically pure product was isolated here.

10


iii) **(2S)-N-Benzyl-(4-fluorophenyl)acetonitrile [(S)-(3)]**



From the product from Example 9A ii), the enantiomerically pure (2S)- N-benzyl-(4-fluorophenyl)acetonitrile was obtained in a yield of 87% (see literature reference 1.), *J.Chem.Soc. Perkin 1 1998*, 3747-3757).

15


iv) (2S)- N-Benzyl-(4-fluorophenyl)glycinamide



(S)-5

5 The enantiomerically pure (2S)- N-benzyl-(4-fluorophenyl)acetonitrile from Example 9A iii) was hydrolysed using conc. sulphuric acid to give (2S)-N-benzyl-(4-fluorophenyl)glycinamide in a yield of 97% (see literature reference 1.), *J.Chem.Soc. Perkin 1* **1998**, 3747-3757).

10 For the conversion of *rac*-(3) into racemic N-benzyl-(4-fluorophenyl)glycinamide, an alternative method using H₂O₂/K₂CO₃ is described in the prior art (see literature reference 3.), Alabaster, R.J., Gibson, A.W., Johnson, S.A., Edwards, J.S., Cottrell, I.F., *Tetrahedron Asymmetry* **1997**, 8, 447-450, cited therein: Alabaster, R.J.; Cottrell, I.F.; Gibson, A.W.; Johnson, S.A.: UK Patent Appl. 9511031.8).

(S)- (4-Fluorophenyl)glycinamide hydrochloride

- 5 For the debenzylation, which has hitherto not been described, of the product from Example 9A iv), a solution of this product (1.5 g, i.e. 5.8 mmol of (2S)-N-benzyl-(4-fluorophenyl)glycinamide) in ethanol (37.5 ml) was admixed with 50% water-moist 5% palladium-on-carbon (1.5 g), ammonium formate (1.5 g, 23.8 mmol) and water (18.8 ml), and this mixture was heated to reflux temperature. After 2 h at reflux, the mixture was filtered, the palladium-on-carbon was washed with cold ethanol (two times 3 ml) and the solution was concentrated. The crude product was stirred with a little ethyl acetate, once more filtered off with suction and concentrated to dryness. The evaporation residue was admixed with 1N HCl in ether and evaporated to dryness. The colourless product was dried under reduced pressure. 0.6 g of the product (S)-4-fluorophenylglycinamide hydrochloride (50% of theory) was isolated. 15 The MS and ¹H-NMR-spectroscopic data corresponded to those given above in Example 9A c).

General procedure for alkylation [A]:

In a typical batch, sodium hydride (6.3 mmol) was, at 0°C, added to a solution of the imidazole of the general formula (III) (6 mmol) in dry DMF (30 ml). After 30 min at room temperature and 30 min at 40°C, the compound of the general formula (II) (6.3 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature overnight. The reaction was then terminated by addition of water, the mixture was extracted with diethyl ether and the organic phase was then dried over sodium sulphate. Chromatography (silica gel, cyclohexane:ethyl acetate) gave the product in a yield of 60-90%.

Alternatively to the reaction of the imidazole with sodium hydride in DMF, it is also possible to carry out the reaction using sodium hydroxide in THF.

General procedure for ester hydrolysis [B]:

In a typical batch, trifluoroacetic acid (5 ml) was added at room temperature to a solution of the ester of the general formula (IV) (T= *tert*-Bu; 1.5 mmol) in dichloromethane (5 ml). After 2 h, the mixture was cooled to 0°C, adjusted to pH = 2 using aqueous sodium hydroxide solution (about 30 ml, 2 M) and extracted with dichloromethane. Drying of the organic phase over sodium sulphate gave, after concentration, the compound of the general formula (V).

General procedure for amide formation [C]:


A suspension of acid (V) (4 mmol), (*S*)-phenylglycinamide hydrochloride (4.2 mmol), 1-hydroxybenzotriazole (4.4 mmol), EDC hydrochloride (4.8 mmol) and triethylamine (12 mmol) in dichloromethane or dimethylformamide (DMF) (40 ml) was stirred at room temperature for 24-48 h. Water was added, and the mixture was then extracted with dichloromethane (in some cases with methanol) and the organic phase was dried over sodium sulphate (or magnesium sulphate) and chromatographed (silica gel, dichloromethane: methanol). This gave the desired product in a yield of 60-80%.

Analogously to procedure C, it is possible to employ phenylglycinol instead of phenylglycinamide.

Preparation Examples

Example 1

- 5 (S)-N-((1*R**, 2*R**)-{4-[2-(2-Aminoethyl-benzimidazol-1-yl)methyl]phenyl}-cyclohex-2-yl-carbonyl)-phenylglycinamide




- Hydrazine hydrate (0.38 ml, 7.82 mmol) was added to a suspension of (2*S*)-N-[(2*R**)-(4-{2-(2-phthaloylaminoethyl)-benzimidazol-1-yl-methyl}-phenyl)-cyclohexyl-(1*R**)-carbonyl]-phenylglycinamide (prepared according to the general procedures [A - C] from the compound of Example 3A and the racemate of Example 2A according to US-A-5,395,840, Example IV; 500 mg, 0.78 mmol, mixture of diastereomers) in ethanol (25 ml). The mixture was stirred at room temperature overnight and then adjusted to pH=2 using hydrochloric acid (1 M) and concentrated. The mixture was partitioned between 10% aqueous sodium bicarbonate solution and dichloromethane and the organic phase was dried over sodium sulphate and chromatographed (silica gel, dichloromethane:methanol:conc. aqueous ammonium 100:13:1.3, R_f(10:1:0.2)=0.1), giving the title compound (292 mg, 72%, mixture of diastereomers) as a yellowish powder. MS(DCI, NH₃)=510 (M+H)⁺. ¹H-NMR(DMSO-*d*₆): 1.2-1.5 (4 H, m); 1.6-1.9 (4 H, m); 2.0 (2 H, br s); 2.6-3.0 (6 H, m); 5.1-5.2 (A:1 H, d; B:1 H, d); 5.4-5.5 (A:2 H, s; B:2 H, s); 6.85-7.0 (4 H, m); 7.1-7.3 (7 H, m); 7.4-7.5 (1 H, m); 7.55-7.65 (4 H, m); 8.05-8.15 (A:1 H, d; B:1 H, d).


25

Example 3


(S)-N-{{(1*R*, 2*R*)-{4-[2-[2-(Morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl)carbonyl}-phenylglycinamide




a) 2-Hydroxymethyl-1*H*-pyrido[2,3-*d*]imidazole



2,3-Diaminopyridine (54.6 g; 0.5 mol) and glycolic acid (38 g; 0.5 mol) in 700 ml of mesitylene were heated under reflux using a Dean-Stark separator until the calculated amount of water had separated out. The mixture was then cooled to room temperature and the resulting precipitate was filtered off with suction and boiled in 800 ml of water, with addition of activated carbon, for 15 min. The hot suspension was filtered and cooled to room temperature, and colourless crystals then precipitated out, which were filtered off with suction and dried. Yield: 56.4 g (75%).

b) 2-Chloromethyl-1*H*-pyrido[2,3-*d*]imidazole hydrochloride:

5 The compound from Example 3a (14.9 g; 100 mmol) was suspended in 25 ml of ethanol, and a stream of dry HCl was introduced until saturation had been reached. The resulting hydrochloride was filtered off with suction and dried under reduced pressure. Yield 18.1 g (100%). The product was suspended in 100 ml of chloroform and admixed with 35 ml of thionyl chloride. The mixture was then heated under
10 reflux for 24 h and then filtered hot, and the precipitate was washed with chloroform and dried under reduced pressure. Yield 18.9 g (92%).


c) 2-(Morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazole:

15

The compound from Example 3b (13.7 g; 67 mmol) and morpholine (28.6 g; 328 mmol) were heated under reflux for 3 h. The mixture was concentrated and the residue was taken up in sodium bicarbonate solution. This suspension was admixed
20 with activated carbon and boiled for 15 min and then filtered whilst still hot. The mixture was concentrated and the resulting product was then purified by column chromatography (silica gel (70-230 mesh ASTM); mobile phase: 100:30:1 ethyl acetate/ethanol/triethylamine). The product can be recrystallized from ethyl acetate/hexane.


25 d) tert-Butyl (1*R*,2*R*)-{4-[[2-(morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl}phenyl}-cyclohexane-1-carboxylate

- 52 -



Under argon, a 60% strength suspension of sodium hydride in oil (2 g; 51.6 mmol) was suspended in 150 ml of DMF, and the compound from Example 3 c) (9.5 g; 43.5 mmol) was added. The mixture was heated at 50°C for 30 min, resulting in the formation of a precipitate. The mixture was then cooled to room temperature and the compound from Example 2A (17.3 g; 44 mmol) was added, and the mixture was then stirred at room temperature for 20 h. The resulting clear solution was concentrated under high vacuum and the residue was taken up in dichloromethane/water. The organic phase was separated off, dried over sodium sulphate and concentrated. The residue was then purified by column chromatography (silica gel (70-230 mesh ASTM); mobile phase: 100:4 dichloromethane/methanol). Yield 10 g (47%) of a brown viscous oil.

- e) (1*R*,2*R*)-2-{4-[[2-(Morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]-methyl]phenyl}cyclohexane-1-carboxylic acid




5

The compound from Example 3d (10 g; 20.4 mmol), 120 ml of dichloromethane and 100 ml of trifluoroacetic acid were stirred at room temperature for 1 h. With cooling, the mixture was then neutralized using concentrated aqueous sodium hydroxide solution, and the organic phase was separated off, dried and concentrated. The residue was purified by column chromatography (mobile phase: dichloromethane/methanol 100:6). Yield 7.3 g (80%) of a colourless amorphous solid.

10

- f) (S)-N-{{{(1*R*,2*R*)-2-{4-[[2-(Morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide

15



20

According to the general procedure [C], the compound from Example 3e (1.4 g; 3.22 mmol) was reacted with addition of a spatula tip of DMAP (4-dimethylaminopyridine). For work-up, the product was extracted with dichloromethane and purified by column chromatography (dichloromethane/methanol 100:6). Yield 1.7 g (93%) of a pale yellowish powder.

25

¹H-NMR (300 MHz; CDCl₃) δ[ppm]: 1.25-1.5 (3H; br m), 1.62 (1H; dq), 1.8 (3H; m), 1.94 (1H; dd), 2.31 (1H; dt), 2.42 (4H; br m), 2.67 (1H; dt), 3.61 (6H; m), 5.21

(1H; d), 5.49 (1H, br s), 5.63 (2H; d+d), 5.72 (1H; br s), 6.41 (1H; d), 6.82 (2H; d), 6.92 (2H; d), 6.98 (2H; d), 7.13 (2H; t), 7.18 (1H; t), 7.23 (1H; dd), 8.03 (1H; d), 8.42 (1H; d)

5 MS (DCI/NH₃)[m/e]: 567 (100, M+H)

Example 4

10 (S)-N-{{{(1R, 2R)-{4-{2-[2-(Morpholin-4-yl-methyl)-1H-pyrido[2,3-d]imidazol-1-yl)methyl]-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide hydrochloride


The compound from Example 3 was dissolved completely in as small an amount of dichloromethane as possible and treated with approximately 2 equivalents of 1M HCl in diethyl ether. The resulting precipitate was filtered off with suction [m.p. 158°C (decomp.)].

15

Example 5

20 (S)-N-{{{(1R, 2R)-2-{4-[[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide


a) *tert*-Butyl (1R, 2R)-2-{4-[(2-chloro-benzimidazol-1-yl)methyl]-phenyl}-cyclohexane-1-carboxylate



25

The title compound was prepared according to the general procedure [A] from 2-chlorobenzimidazole and the compound from Example 2A [R_f⁻(cyclohexane:ethyl acetate = 1:1) = 0.85].

b) (1*R*,2*R*)-2-{4-[[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl]-phenyl}-cyclohexane-1-carboxylic acid




5

A solution of the compound from Example 5a (34.0 g, 56.0 mmol) in N-methyl-piperazine (77.7 ml, 700 mmol) was heated at 100°C overnight and then concentrated and chromatographed (silica gel, dichloromethane:methanol = 20:1 to 10:1, R_f (10:1)=0.32). This gave 32.0 g of *tert*-butyl (1*R*, 2*R*)-2-{4-[[2-(4-methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl]-phenyl}-cyclohexane-1-carboxylate which were
 10 reacted at room temperature with hydrochloric acid (180 ml, 6 M) overnight. The reaction mixture was washed at pH=7 with dichloromethane and the organic phase was dried over magnesium sulphate and chromatographed (silica gel, dichloromethane:methanol 5:1, R_f =0.13), giving 19 g (78% of theory over 2 steps) of the title
 15 compound. MS(ESI)=433 ($M+H^+$). 1H -NMR(DMSO- d_6): 1.35-1.5 (4 H, m); 1.65-1.8 (3 H, m); 1.9-2.0 (1 H, m); 2.2 (3 H, s); 2.4-2.5 (5 H, m); 2.6-2.7 (1 H, m); 3.15 (4 H, ψ t); 3.4 (1 H, very br s); 5.2 (2 H, s); 7.0-7.2 (7 H, m); 7.4 (1 H, d).

c) (S)-N-{{(1*R*,2*R*)-2-{4-[[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl]-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide


20



A suspension of the compound from Example 5b (19 g, 43.9 mmol), (*S*)-phenylglycinamide hydrochloride (8.61 g, 46.1 mmol), 1-hydroxybenzotriazol (7.68 g, 48.3 mmol), EDC hydrochloride (9.68 g, 50.5 mmol) and triethylamine (24.5 ml, 175.7 mmol) in dichloromethane (1000 ml) was stirred at room temperature over the weekend. After addition of water, the mixture was extracted with dichloromethane/methanol and the extract was dried over magnesium sulphate and concentrated. The slightly yellowish solid was stirred with dichloromethane/methanol (10:1, 220 ml) and the pure title compound was filtered off and dried under reduced pressure at 40°C (14.5 g, 59%). R_f (dichloromethane:methanol 10:1)=0.30. MS(DCI, NH_3)=565 ($\text{M}+\text{H}^+$). $^1\text{H-NMR}$ (DMSO- d_6): 1.2-1.5 (4 H, m); 1.6-1.85 (4 H, m); 2.2 (3 H, s); 2.45 (4 H, ψ t); 2.65 (1 H, br t); 2.8 (1 H, td); 3.15 (4 H, ψ t); 5.15 (1 H, d); 5.2 (2 H, s); 6.9 (2 H, d); 6.95-7.2 (11 H, m); 7.45 (1 H, d); 7.6 (1 H, br s); 8.0 (1 H, d).

Example 6

(*S*)-N-{{(1*R*, 2*R*)-2-[4-{{2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl}methyl}-phenyl]-cyclohex-1-yl}carbonyl}-phenylglycinamide hydrochloride







The compound from Example 5 (100 mg, 0.177 mmol) was dissolved in dichloromethane/methanol (2.5:1; 5 ml) and admixed with 1M HCl/diethyl ether (0.177 mmol), and the mixture was stirred for 5 min and then concentrated cold under reduced pressure. The title compound was obtained as a colourless powder (106 mg). M.p. 200°C (decomp.).

The Examples 7 to 10 listed in Table 1 below were prepared analogously to Example 5 using the appropriately substituted piperazines.

Table 1:

5

Ex. No.	Structure	R _f *
7		0.3 (10:1:0)
8		0.3 (10:1:0.1)
9		0.4 (10:1:0.1)
10		0.3 (10:1:0.1)

* CH₂Cl₂:methanol:conc. ammonia


The Examples 11 and 12 listed in Table 2 below are prepared starting with the compound from Example 6A, according to the general procedures A, B and C: ---

Table 2:

Ex. No.	Structure	R_f *
11		0.4 (10:1)
12		0.35 (10:1)

Example 13

(*S*)-N-{{(1*R*, 2*R*)-2-{4-[[2-(2-Hydroxyethoxy)methyl]-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl}carbonyl}-phenylglycinamide



The title compound is obtained starting with the compound of Example 7A, which is silylated analogously to Example 6A using TBDMS chloride and then reacted according to the general procedures A, B and C.

$R_f(\text{dichloromethane:methanol } 20:1)=0.20$.

MS(ESI)=541 ($M+H^+$). $^1\text{H-NMR}(\text{DMSO}-d_6)$: 1.2-1.5 (4 H, m); 1.6-1.9 (4 H, m); 2.6-2.7 (1 H, m); 2.75-2.85 (1 H, m); 3.5 (4 H, s); 4.65 (1 H, br s); 4.6 (2 H, s); 5.15 (1 H, d); 5.55 (2 H, s); 6.9 (2 H, d); 6.95-7.2 (10 H, m); 7.45 (1 H, m); 7.6 (1 H, s); 7.65 (1 H, m); 8.05 (1 H, d).


The Examples 14 to 16 listed in Table 3 below are prepared analogously to Example 13 from the appropriate starting materials.

Table 3:


Ex. No.	Structure	R _f (CH ₂ Cl ₂ :MeOH: conc. ammonia)	MS
14		0.44 (10:1:0)	
15		0.46 (10:1:0)	
16			El: 541 (M ⁺)

Example 17

(S)-N-(((1R,2R)-2-{4-[[2-(3-Hydroxypropyl)-1H-benzimidazol-1-yl]methyl]phenyl}-cyclohex-1-yl]carbonyl)-(4-fluorophenyl)glycinamide:



a) *tert*-Butyl (1R,2R)-2-(4-[[2-(3-[[*tert*-butyl(dimethyl)silyl]oxy]propyl)-1H-benzimidazol-1-yl]methyl]phenyl)cyclohexane-1-carboxylate:




The 2-(3-[[*tert*-butyl(dimethyl)silyl]oxy]propyl)-1H-benzimidazole from Example 8A (22.01 g, 75.77 mmol) was added in portions to a suspension of NaH (60% in mineral oil, 3.03 g, 75.77 mmol) in DMF (480 ml). After 15 min at RT, the mixture was heated to 40°C, and stirring was continued for 30 min. After cooling to RT, the compound from Example 2A (25.5 g, 72.17 mmol) was added a little at a time, and the mixture was stirred overnight. 50 ml of water were added, the mixture was extracted with diethyl ether and the organic phase was dried over sodium sulphate and chromatographed over silica gel (mobile phase: cyclohexane/ethyl acetate = 10:1 to 5:1), giving 38.86 g (95.7%) of a colourless solid.

MS (ESI): 563.3 (M+H)⁺

¹H-NMR (DMSO-d₆): 0.00 (3 H, s); 0.01 (3 H, s); 0.85 (9 H, s); 0.99 (9 H, s); 1.3-2.0 (10 H, m); 2.3-2.6 (2 H, m); 2.87 (2 H, t); 3.69 (2 H, t); 5.41 (2 H, s); 6.95-7.18 (6 H, m); 7.38-7.59 (2 H, m)

b) *tert*-Butyl (1*R*,2*R*)-2-(4-{[2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl]-methyl}phenyl)cyclohexane-1-carboxylate:



5

I.)

A solution of tetrabutylammonium fluoride (TBAF) in THF (1.1M, 68.9 ml, 75.83 mmol) was added dropwise to a solution of the compound from Example 17a (38.80 g, 68.93 mmol) in THF (750 ml), and the mixture was stirred at RT for 30 min. The mixture was extracted with diethyl ether and the organic phase was dried over sodium sulphate and chromatographed over silica gel (mobile phase: dichloromethane/methanol = 95:5), giving 29.0 g (93.8%) of a colourless solid.

10

MS (ESI): 449.5 (M+H)⁺

15

¹H-NMR (DMSO-d₆): 0.99 (9 H, s); 1.25-1.55 (4 H, m); 1.6-1.8 (3 H, m); 1.8-2.0 (3 H, m); 2.3-2.65 (2 H, m); 2.86 (2 H, t); 3.49 (2 H, q); 4.60 (1 H, t); 5.42 (2 H, s); 6.99 (2 H, m); 7.08-7.18 (4 H, m); 7.33-7.44 (1 H, m); 7.5-7.6 (1 H, m).

20

II.)

The compound of Example 17b) can also be prepared by coupling 2-(3-hydroxypropyl)-1*H*-benzimidazole directly to the compound from Example 2A, analogously to the general procedure for alkylation A.

25


To this end, a 60% suspension of sodium hydride in mineral oil (880 mg, 22 mmol) was initially charged in DMF (10 ml), 2-(3-hydroxypropyl)-1*H*-benzimidazole (3.52 g, 20 mmol), dissolved in DMF (50 ml), was added, the mixture was stirred at RT for 10 min and then heated at 40°C for 30 min. After cooling to RT, the compound from Example 2A (7.07 g, 20 mmol), dissolved in DMF (50 ml), was added, and the reaction mixture was stirred at RT overnight. For work-up, the

30

5 mixture was shaken with water and ethyl acetate, the aqueous phase was re-extracted twice with ethyl acetate and the combined organic phases were washed once with saturated sodium chloride solution. After drying over sodium sulphate, the solvent was removed under reduced pressure and the residue was crystallized by stirring with diethyl ether / petroleum ether (5:1, 70 ml). The crystalline compound was filtered off and washed with petroleum ether. Drying under reduced pressure gave 6.62 g (74% of theory) of a colourless solid which, according to spectroscopic characterization, is identical to the compound of Example 17b) I.).

Example 18

(S)-N-{[(1*R*,2*R*)-2-{4-{[2-(hydroxymethyl)-1*H*-benzimidazol-1-yl]methyl}-phenyl]-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:



5

Starting with the compounds of Examples 2A, 6A and 9A c) or v), the title compound was prepared analogously to the process described in Example 17. Instead of removing the protective groups in two steps, the *tert*-butyldimethylsilyl ether and the *tert*-butyl ester of the intermediate analogous to Example 17 a) were removed in one step by action of concentrated hydrochloric acid.

10

R_f (dichloromethane/methanol = 10:1): 0.38


15 MS (ESI): 515 (M+H)⁺

¹H-NMR (DMSO-*d*₆): 1.20-1.50 (4 H, m); 1.61-1.78 (3 H, m); 1.78-1.86 (1 H, br. d); 2.65 (1 H, br. t); 2.80 (1 H, br. t); 4.71 (2 H, br. d); 5.15 (1 H, d); 5.48 (1 H, d; AB-System); 5.53 (1 H, d); 5.72 (1 H, t); 6.87-6.94 (4 H, m); 7.03-7.09 (2 H, m); 7.09-7.19 (5 H, m); 7.37 (1 H, m); 7.58-7.65 (2 H, m); 8.09 (1 H, d).

20

Patent Claims

1. Compounds of the general formula (I)



in which

A, D, E and G are identical or different and represent CH groups or nitrogen atoms,

L¹ and L² are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy or (C₁-C₆)-alkoxycarbonyl,

R¹ represents the CH₂-OH group, or
represents a radical of the formula CO-NR⁴R⁵,

in which

R⁴ and R⁵ are identical or different and each represents hydrogen or (C₁-C₆)-alkyl,

R² represents (C₃-C₈)-cycloalkyl,
represents (C₁-C₈)-alkyl which is optionally interrupted by an oxygen or sulphur atom or by a radical NR⁶,
represents a 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom, or
represents a 4- to 8-membered saturated heterocycle which contains a radical of the formula NR⁷ and optionally additionally one nitrogen, oxygen or sulphur atom,

where (C₃-C₈)-cycloalkyl, (C₁-C₈)-alkyl which is optionally interrupted by an oxygen or sulphur atom, the 4- to 8-membered saturated heterocycle which is attached to the imidazole ring via a nitrogen atom and which optionally contains a further oxygen or sulphur atom and optionally (C₁-C₈)-alkyl which is interrupted by a radical of the formula NR⁶ and optionally the 4- to 8-membered saturated heterocycle which contains a radical NR⁷ and optionally additionally one nitrogen, oxygen or sulphur atom are substituted by one to three hydroxyl groups and/or by a radical of the formula -NR⁸R⁹

in which

R⁶ and R⁷ are identical or different and each represents hydrogen, (C₁-C₆)-alkyl, hydroxy-(C₁-C₆)-alkyl or (C₃-C₇)-cycloalkyl,

R⁸ and R⁹ are identical or different and each represents hydrogen, (C₁-C₆)-alkyl or (C₃-C₇)-cycloalkyl,

OF

R⁸ and R⁹ together with the nitrogen atom form a 4- to 8-membered saturated heterocycle which may optionally additionally contain one oxygen or sulphur atom or a radical of the formula NR¹⁰,

in which

R^{10} represents hydrogen, (C₁-C₆)-alkyl or (C₃-C₇)-cyclo-alkyl,

5

and

R^3 represents a phenyl, naphthyl, pyrimidinyl, pyridyl, furyl or thienyl ring, where the rings are optionally mono- or polysubstituted by radicals selected from the group consisting of halogen, hydroxyl, carboxyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy and (C₁-C₆)-alkoxycarbonyl,

10

and their enantiomers and diastereomers and their respective salts, hydrates and, if appropriate, their prodrugs.

15

2. Compounds according to Claim 1

where

20

A, D, E and G each represent the CH group,

or one of the radicals A, D, E and G represents a nitrogen atom and the others each represent the CH group,

25

L^1 and L^2 are identical or different and independently of one another each represents one or more radicals selected from the group consisting of hydrogen, fluorine, chlorine, cyano, trifluoromethyl and trifluoromethoxy,

30

R^1 represents the -CH₂-OH group, or represents a radical of the formula -CO-NR⁴R⁵,

in which

where (C₁-C₄)-alkyl, which is optionally interrupted by an oxygen atom, is substituted by a hydroxyl group or by a radical of the formula -NR⁸R⁹,

in which

R⁷ represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

R⁸ and R⁹ are identical or different and each represents hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

or

R⁸ and R⁹ together with the nitrogen atom form a morpholine radical,

and

R³ represents a phenyl or pyridyl radical which may optionally be mono- or polysubstituted by fluorine,

and their enantiomers and diastereomers and their respective salts, hydrates and, if appropriate, their prodrugs.

4. Compounds according to any of Claims 1 to 3


where

the radical R¹ represents a radical of the formula CO-NR⁴R⁵ where R⁴ and R⁵ are as defined above

and

the other radicals are as defined in Claims 1 to 3.

5. Compounds according to any of Claims 1 to 4, characterized by the following stereochemistry according to formula (Ia):




5

where the substituents R¹, R², R³, L¹ and L² and the radicals A, D, E and G are each as defined in Claims 1 to 4.

6. Compounds according to any of Claims 1 to 5, characterized by the following stereochemistry according to formula (Ib)

10



in which

15

R¹ represents a group -C(O)-NH₂,

R² represents (C₁-C₄)-alkyl which is substituted at the terminal C atom by a hydroxyl group,

20

R³ represents a phenyl ring which is optionally substituted in the para position by fluorine,


or

represents a pyridyl radical,

and their diastereomers and their respective salts, hydrates and, if appropriate, their prodrugs.

5


7. Compounds of the general formula (I) of the following structures:
 (S)-N-[[[(1R,2R)-2-{4-[[2-(3-hydroxypropyl)-1H-benzimidazol-1-yl]methyl]-phenyl]-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:



10


and their salts, hydrates and, if appropriate, their prodrugs.

(S)-N-[[[(1R,2R)-2-{4-[[2-(2-hydroxymethyl)-1H-benzimidazol-1-yl]methyl]-phenyl]-cyclohex-1-yl]carbonyl}-(4-fluorophenyl)glycinamide:




(S)-N-[[[(1R,2R)-2-{4-[[2-(2-hydroxyethyl)-1H-benzimidazol-1-yl]methyl]-phenyl]-cyclohex-1-yl]carbonyl}-phenyl]glycinamide:


(*S*)-N-{{[(1*R*,2*R*)-2-{4-[[2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl]methyl]-phenyl]-cyclohex-1-yl}carbonyl}-(3-pyridyl)glycinamide:



(*S*)-N-{{[(1*R*,2*R*)-4-{2-[2-(morpholin-4-yl-methyl)-1*H*-pyrido[2,3-*d*]imidazol-1-yl]methyl]-phenyl]-cyclohex-1-yl}carbonyl}-phenylglycinamide:




(*S*)-N-{{[(1*R*,2*R*)-2-{4-[[2-(3-hydroxypropyl)-1*H*-benzimidazol-1-yl]methyl]-phenyl]-cyclohex-1-yl}carbonyl}-(4-fluorophenyl)glycinamide:



8. Process for preparing compounds of the general formula (I) according to Claims 1 to 7, characterized in that

5

[A] compounds of the general formula (II)



in which


L^2 is as defined above,

T represents (C₁-C₄)-alkyl, preferably methyl or tert-butyl,

and

V represents a suitable leaving group, such as, for example, halogen, mesylate or tosylate, preferably bromine,

are initially converted by reaction with compounds of the general formula (III)



in which


A, D, E, G and L^1 are each as defined above

and

R^{11} has the meaning of R^2 given above, where amino and hydroxyl functions are optionally blocked by suitable amino- or hydroxyl-protective groups,

in inert solvents, depending on the definition of R¹¹ optionally in the presence of a base, into the compounds of the general formula (IV)

- 80 -




in which

R^{11} , A, D, E, G, L^1 , L^2 and T are each as defined above,

5

which are converted in a subsequent step using acids or bases into the corresponding carboxylic acids of the general formula (V)



10

in which


R^{11} , A, D, E, G, L^1 and L^2 are each as defined above,

15

which are, if appropriate, activated, in particular by conversion into a corresponding carboxylic acid derivative, such as carbonyl halide, carboxylic anhydride or carboxylic ester,

and which are subsequently reacted by known methods with compounds of the general formula (VI) or salts thereof

20



in which

R^1 and R^3 are each as defined above


in inert solvents,

and, if R^{II} carries one of the abovementioned protective groups, this is optionally removed by customary methods either in the hydrolysis to the acids (IV) \rightarrow (V) or after the reaction with the compounds of the general formula (VI),

or

[B] if R² represents a saturated heterocycle which is attached directly to the imidazole ring via a nitrogen atom,

the abovementioned compounds of the general formula (II) are initially converted with compounds of the general formula (IIIa)



in which


A, D, E, G and L¹ are each as defined above

and

Y represents halogen or mesylate, preferably chlorine, bromine or mesylate,

in inert solvents into the corresponding compounds of the formula (VII)

- 82 -



in which

Y, A, D, E, G, L¹, L² and T are each as defined above,


which are reacted in a subsequent step with compounds of the general formula (VIII)



in which

R¹² and R¹³ together with the nitrogen atom form a heterocycle according to the definition of R²


to give compounds of the general formula (IX)



in which

A, D, E, G, L¹, L², R¹², R¹³ and T are each as defined above,

which are, in the subsequent steps, converted as described under [A] by hydrolysis into the corresponding carboxylic acids of the general formula (X)




in which

A, D, E, G, L¹, L², R¹² and R¹³ are each as defined above

and these compounds are finally reacted with the compounds of the general formula (VI) according to known methods for preparing amides from carboxylic acids and amines and converted into the compounds of the general formula (I)

where the compounds of the general formula (I) obtained according to process variant [A] or [B] can, if appropriate, subsequently be converted into the corresponding salts by reaction with, for example, an acid.

9. Compounds of the general formula (IV)




in which

A, D, E, G, L¹, L², R¹¹ and T are each as defined above,

and their enantiomers and diastereomers and their respective salts.

10. Compounds of the general formula (V)

5



in which


A, D, E, G, L¹, L² and R¹¹ are each as defined above,

10

and their enantiomers and diastereomers and their respective salts.

11. Compounds of the general formula (VII)

15




in which

A, D, E, G, L¹, L², Y and T are each as defined above,

and their enantiomers and diastereomers and their respective salts.

20

12. Compounds of the general formula (IX)




in which

A, D, E, G, L¹, L², R¹², R¹³ and T are each as defined above,

and their enantiomers and diastereomers and their respective salts.

13. Compounds of the general formula (X)




in which

A, D, E, G, L¹, L², R¹¹ and R¹² are each as defined above.


and their enantiomers and diastereomers and their respective salts.

14. (S)-(4-Fluorophenyl)glycinamide



and its salts.

15. (S)-(3-Pyridyl)glycinamide



and its salts.

5

16. Medicaments, comprising a compound of the general formula (I) according to any of Claims 1 to 7 in admixture with at least one pharmaceutically acceptable, essentially non-toxic carrier or excipient.

10

17. Compounds according to any of Claims 1 to 7 for use as medicament in the treatment of humans and animals.

18. Compounds according to any of Claims 1 to 7 for the prophylaxis and/or treatment of disorders in humans and animals.

15


19. Use of compounds according to any of Claims 1 to 7 for preparing medicaments for the prophylaxis and/or treatment of disorders in humans and animals.

20

20. Use of compounds according to any of Claims 1 to 7 for preparing medicaments for the treatment and/or prophylaxis of ischaemic disorders of the cardiovascular system.

Substituted phenylcyclohexanecarboxamides**Abstract**

The present invention relates to substituted phenylcyclohexanecarboxamides of the formula (I), to processes for their preparation and to their use in medicaments, in particular for treating cardiovascular disorders.



COMBINED DECLARATION AND POWER OF ATTORNEY

ATTORNEY DOCKET NO

Le A 33 535

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

"SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THEIR USE AS ADENOSINE UPTAKE INHIBITORS"

the specification of which is attached hereto,

or was filed on **May 16, 2000**

as a PCT Application Serial No. **PCT/EP00/04431**

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s), the priority(ies) of which is/are to be claimed:

199 24 819.2
(Number)

Germany
(Country)

May 29, 1999
(Month/Day/Year Filed)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose the material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Le A 33 535-US

JK

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Jeffrey M. Greenman, Reg.No. 26552
Barbara A. Shimei, Reg. No. 29862
William F. Gray, Reg. No. 31018
Alice A. Brewer, Reg. No. 32888
Jerrie L. Chiu, Reg. No. 41670

Susan M. Pellegrino, Reg. No. 48972

all of Bayer Corporation, 400 Morgan Lane, West Haven, Connecticut 06516

Send Correspondence To: <u>Mr. Jeffrey M. Greenman</u> <u>Bayer Corporation</u> <u>400 Morgan Lane</u> <u>West Haven, Connecticut 06516</u>	Direct Telephone Calls To: (203)812-3964(Jerrie L. Chiu)
---	---

107	FULL NAME OF SOLE OR FIRST INVENTOR <u>Erwin Bischoff</u>	INVENTOR'S SIGNATURE <i>Erwin Bischoff</i>	DATE <u>2001-09-12</u>
RESIDENCE D 42115 Wuppertal, Germany		CITIZENSHIP German	
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany			
FULL NAME OF SECOND INVENTOR Stephan Lensky	INVENTOR'S SIGNATURE <i>Stephan Lensky</i>	DATE	
RESIDENCE D 51515 Kürten, Germany	CITIZENSHIP US		
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany			
FULL NAME OF THIRD INVENTOR Stephan-Nicholas Müller	INVENTOR'S SIGNATURE <i>Stephan-Nicholas Müller</i>	DATE <u>2001-09-11</u>	
RESIDENCE D 42105 Wuppertal, Germany	CITIZENSHIP German		
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany			
FULL NAME OF FOURTH INVENTOR Holger Paulsen	INVENTOR'S SIGNATURE <i>Holger Paulsen</i>	DATE	
RESIDENCE D 42115 Wuppertal, Germany	CITIZENSHIP German		
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany			
FULL NAME OF FIFTH INVENTOR Jörg Keldenich	INVENTOR'S SIGNATURE <i>Jörg Keldenich</i>	DATE <u>01-09-11</u>	
RESIDENCE D 42113 Wuppertal, Germany	CITIZENSHIP German		
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany			
FULL NAME OF SIXTH INVENTOR Thomas Krahn	INVENTOR'S SIGNATURE <i>Thomas Krahn</i>	DATE <u>01-09-11</u>	
RESIDENCE D 58135 Hagen, Germany	CITIZENSHIP German		
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany			
FULL NAME OF SEVENTH INVENTOR Joachim Schuhmacher	INVENTOR'S SIGNATURE <i>Joachim Schuhmacher</i>	DATE <u>20-9-01</u>	
RESIDENCE D 42113 Wuppertal, Germany	CITIZENSHIP German		
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany			

FULL NAME OF EIGHTH INVENTOR Jan Jänichen	INVENTOR'S SIGNATURE <i>Jan Jänichen</i>	DATE 01-10-05
RESIDENCE D 22149 Hamburg, Germany	CITIZENSHIP German	
POST OFFICE ADDRESS Am Sooren 13, D 22149 Hamburg, Germany		
FULL NAME OF NINTH INVENTOR Wolfgang Thielemann	INVENTOR'S SIGNATURE <i>Wolfgang Thielemann</i>	DATE 01-09-19
RESIDENCE D 42107 Wuppertal, Germany	CITIZENSHIP German	
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany		
FULL NAME OF TENTH INVENTOR Henning Steinhagen	INVENTOR'S SIGNATURE <i>Henning Steinhagen</i>	DATE 2001-03-20
RESIDENCE D 42113 Wuppertal, Germany	CITIZENSHIP German	
POST OFFICE ADDRESS c/o Bayer Aktiengesellschaft, D 51368 Leverkusen, Germany		
FULL NAME OF ELEVENTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF TWELFTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF THIRTEENTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF FOURTEENTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF FIFTEENTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SIXTEENTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SEVENTEENTH INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

DLK